View Filing Data

Print Document View Excel Document

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Dec. 31, 2017	Mar. 01, 2018	Jun. 30, 2017
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	FY
Trading Symbol	FLGT
Entity Registrant Name	Fulgent Genetics, Inc.
Entity Central Index Key	0001674930
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		17,866,870
Entity Public Float			$ 33.7

Consolidated Balance Sheets - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 6,490,000	$ 7,897,000
Marketable securities	19,994,000	12,971,000
Trade accounts receivable, net of allowance for doubtful accounts of $287 and $151, as of December 31, 2017 and 2016, respectively	4,005,000	4,364,000
Other current assets	2,438,000	906,000
Total current assets	32,927,000	26,138,000
Marketable securities, long term	14,883,000	25,597,000
Equity method investments	1,937,000	0
Fixed assets, net	7,272,000	6,234,000
Deferred tax asset	126,000	54,000
Other long-term assets	39,000	17,000
Total assets	57,184,000	58,040,000
Current liabilities
Accounts payable	2,089,000	2,756,000
Accrued liabilities	911,000	436,000
Income tax payable		124,000
Total current liabilities	3,000,000	3,316,000
Other long-term liabilities	6,000	2,000
Deferred tax liability		243,000
Total liabilities	3,006,000	3,561,000
Commitments and contingencies (Note 8)
Stockholders’ equity
Common stock, $0.0001 par value per share, 50,000 and 200,000 shares authorized, 17,847 and 17,676 shares issued and outstanding at December 31, 2017 and 2016, respectively.	2,000	2,000
Preferred stock, $0.0001 par value per share, 1,000 shares authorized, no shares issued or outstanding at December 31, 2017 and 2016
Additional paid-in capital	111,884,000	109,734,000
Accumulated other comprehensive income (loss)	(44,000)	(103,000)
Accumulated deficit	(57,664,000)	(55,154,000)
Total stockholders’ equity	54,178,000	54,479,000
Total liabilities and stockholders’ equity	$ 57,184,000	$ 58,040,000

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts receivable	$ 287	$ 151
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	50,000,000	200,000,000
Common stock, shares issued	17,847,000	17,676,000
Common stock, shares outstanding	17,847,000	17,676,000
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Consolidated Statements of Operations - USD ($) shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Statement [Abstract]
Revenue	$ 18,730,000	$ 18,276,000
Cost of revenue	8,551,000	6,722,000
Gross profit	10,179,000	11,554,000
Operating expenses:
Research and development	4,223,000	3,558,000
Selling and marketing	4,205,000	2,469,000
General and administrative	5,233,000	4,609,000
Total operating expenses	13,661,000	10,636,000
Operating income (loss)	(3,482,000)	918,000
Interest and other income (expense)	481,000	(5,386,000)
Income (loss) before income taxes and equity loss in investee	(3,001,000)	(4,468,000)
Provision for (benefit from) income taxes	(1,015,000)	920,000
Income (loss) before equity loss in investee	(1,986,000)	(5,388,000)
Equity loss in investee	(524,000)	0
Income (loss) from continuing operations	(2,510,000)	(5,388,000)
Income (loss) from discontinued operations	0	41,000
Net income (loss)	$ (2,510,000)	$ (5,347,000)
Income (loss) per common share:
Basic and Diluted	$ (0.14)	$ (1.00)
Weighted-average common shares:
Basic and Diluted	17,739	13,710

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss)	$ (2,510)	$ (5,347)
Other comprehensive income (loss), net of tax:
Foreign currency translation gain (loss)	81
Net unrealized gain (loss) on marketable securities	(22)	(103)
Comprehensive income (loss)	$ (2,451)	$ (5,450)

Consolidated Statements of Stockholders'/ Members' Equity - USD ($) $ in Thousands	Total	Initial Public Offering	Class D-2 Preferred Units	Class D-1 Preferred Units	Class D Common Units	Members' Equity	Members' Equity Class D-2 Preferred Units	Members' Equity Class D-1 Preferred Units	Members' Equity Class D Common Units	Stockholders' Equity	Stockholders' Equity Initial Public Offering	Additional Paid-In Capital	Additional Paid-In Capital Initial Public Offering	Accumulated Other Comprehensive Loss	Accumulated Deficit	Accumulated Deficit Class D-1 Preferred Units	Accumulated Deficit Class D Common Units
Beginning Balance at Dec. 31, 2015	$ 5,146					$ 58,306									$ (53,160)
Beginning Balance, Shares at Dec. 31, 2015						186,000,000
Split-off of Pharma business	(490)					$ (12,390)									11,900
Split-off of Pharma business, Shares						(96,000,000)
Issuance of units / shares, Amount		$ 35,989	$ 32,452				$ 32,452						$ 35,989
Issuance of units / shares							15,395,000				4,830,000
Repurchase and retirement				$ (1,663)	$ (6,587)			$ (1,663)	$ (1,767)								$ (4,820)
Repurchase and retirement, Shares								(4,618,000)	(5,645,000)
Deemed dividend on retirement of Class D-1 preferred units				(3,727)												$ (3,727)
Equity-based compensation (Pre-Reorganization)	2,978					$ 2,978
Equity-based compensation (Pre-Reorganization), Shares						2,500,000
Distribution to Class D-1 preferred unitholder				$ (4,592)				$ (4,592)
Tax distribution to Class D common and preferred unitholders					$ (1,253)				$ (1,253)
Reorganization (Note 1)						$ (72,071)				$ 2		$ 72,069
Reorganization, Shares (Note 1)						(97,632,000)				12,846,000
Equity-based compensation (Post-Reorganization)	1,676											1,676
Other comprehensive income (loss), net	(103)													$ (103)
Net loss	(5,347)														(5,347)
Ending Balance at Dec. 31, 2016	$ 54,479									$ 2		109,734		(103)	(55,154)
Ending Balance, Shares at Dec. 31, 2016	17,676,000									17,676,000
Equity-based compensation	$ 2,119											2,119
Exercise of common stock options	31											31
Exercise of common stock options, Shares										81,000
Restricted stock awards, Shares										90,000
Other comprehensive income (loss), net	59													59
Net loss	(2,510)														(2,510)
Ending Balance at Dec. 31, 2017	$ 54,178									$ 2		$ 111,884		$ (44)	$ (57,664)
Ending Balance, Shares at Dec. 31, 2017	17,847,000									17,847,000

Consolidated Statements of Stockholders'/ Members' Equity (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2016 USD ($)
Class D-2 Preferred Units
Preferred units issuance cost, net	$ 185

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Cash flow from operating activities:
Net income (loss)	$ (2,510,000)	$ (5,347,000)
Income (loss) from discontinued operations	0	41,000
Loss from continuing operations	(2,510,000)	(5,388,000)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Equity-based compensation	2,119,000	4,654,000
Depreciation and amortization	1,728,000	1,170,000
Loss (gain) on disposal of fixed asset	5,000
Amortization of premium of marketable securities	370,000	63,000
Provision for bad debt	160,000	76,000
Deferred income taxes	(336,000)	246,000
Fair value adjustment recorded upon issuance of Class D-2 preferred units		5,472,000
Equity loss in investee	524,000	0
Other	(15,000)
Changes in operating assets and liabilities:
Accounts receivable	214,000	(2,322,000)
Other current assets	(1,537,000)	(381,000)
Accounts payable	(363,000)	1,094,000
Taxes payable	(124,000)	124,000
Accrued liabilities	1,098,000	(372,000)
Other current liabilities	(2,000)
Cash provided by continuing operations	1,331,000	4,436,000
Cash used in discontinued operations		(31,000)
Net cash provided by operating activities	1,331,000	4,405,000
Cash flow from investing activities:
Purchases of fixed assets	(2,895,000)	(3,788,000)
Proceeds from disposal of fixed assets		10,000
Sale of marketable securities	3,781,000
Purchase of marketable securities	(11,659,000)	(39,017,000)
Maturities of marketable securities	11,185,000
Purchase of equipment contributed to Equity Method Investee	(2,461,000)
Net cash used in investing activities	(2,049,000)	(42,795,000)
Cash flow from financing activities:
Proceeds from issuance of common stock, net of offering costs		36,790,000
Cash distributed in split-off of Pharma business		(159,000)
Distribution to Class D-1 preferred unitholder		(4,592,000)
Payment of initial public offering costs	(801,000)
Proceeds from issuance of Class D-2 preferred units		26,980,000
Repurchase and retirement of Class D-1 preferred and Class D common units		(11,977,000)
Tax distribution to Class D common and preferred unitholders		(1,253,000)
Proceeds from exercise of stock options	31,000
Net cash provided by (used in) financing activities	(770,000)	45,789,000
Effect of exchange rate changes on cash and cash equivalents	81,000
Net increase (decrease) in cash	(1,407,000)	7,399,000
Cash balance at beginning of period	7,897,000	498,000
Cash balance at end of period	6,490,000	7,897,000
Supplemental disclosures of cash flow information:
Income taxes paid	757,000	550,000
Supplemental disclosures of non-cash investing and financing activities:
Fixed assets included in accounts payable	$ 1,014,000	1,173,000
Initial public offering costs included in accounts payable and accrued expenses		$ 801,000

Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Statement Of Cash Flows [Abstract]
Cash from discontinued operations, beginning	$ 0	$ 9
Cash from discontinued operations, ending	$ 0	$ 0

Overview and Basis of Presentation

12 Months Ended

Dec. 31, 2017

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Overview and Basis of Presentation

Note 1. Overview and Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). These financial statements include the assets, liabilities, revenues and expenses of all wholly-owned subsidiaries and entities in which the Company has a controlling financial interest or is deemed to be the primary beneficiary. In determining whether the Company is the primary beneficiary of an entity, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. The Company uses the equity method to account for its investments in entities that it does not control, but in which it has the ability to exercise significant influence over operating and financial policies. All significant intercompany accounts and transactions are eliminated from the accompanying consolidated financial statements.

Nature of the Business

Fulgent Genetics, Inc., together with its subsidiaries (collectively referred to as the “Company,” unless otherwise noted or the context otherwise requires), is a growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the quality of patient care (the “Diagnostics business”). The Company has developed a proprietary technology platform that allows it to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library. The Company’s test menu currently includes single-gene tests and pre-established, multi-gene, disease-specific panels that collectively test for many genetic conditions, including various cancers, cardiovascular diseases, neurological disorders and pediatric conditions. The Company’s existing customer base consists primarily of hospitals and medical institutions, which are typically frequent and high-volume users of genetic tests and which often pay the Company directly for its tests.

Background and Reorganization

The Company was incorporated in the State of Delaware on May 13, 2016. On August 2, 2016, pursuant to the approval of the board of directors of the Company, the Company changed its name from Fulgent Diagnostics, Inc. to Fulgent Genetics, Inc. On September 30, 2016, the Company completed a reorganization pursuant to which Fulgent Therapeutics LLC, a California limited liability company (referred to, together with its former subsidiary unless otherwise noted or the context otherwise requires, as “Fulgent LLC”), became a wholly owned subsidiary of the Company (the “Reorganization”). Prior to the Reorganization, the Company had no material assets and had not conducted any activities other than those incidental to its incorporation and preparation for the initial public offering of its common stock. Following the Reorganization, the Company is a holding company with no material assets other than 100% of the equity interests in Fulgent LLC and its other subsidiaries, and Fulgent LLC is considered the Company’s predecessor for accounting purposes and Fulgent LLC’s financial statements for all periods prior to completion of the Reorganization constitute the Company’s historical financial statements.

For purposes of these notes and the accompanying consolidated financial statements: (i) Fulgent LLC’s operating agreement, as amended from time to time, is referred to as the “Operating Agreement;” (ii) Fulgent LLC’s equity holders are referred to as “members;” (iii) Fulgent LLC’s authorized, issued and outstanding equity interests prior to the Reorganization are referred to as “units” and consisted of Class D common units and Class D-1 and Class D-2 preferred units; (iv) certain of Fulgent LLC’s Class D common units outstanding prior to the Reorganization constituted profits interests (which are sometimes referred to simply as “profits interests”), which are a type of equity-based award containing a participation threshold (which is sometimes referred to as a “profits interest threshold”) that entitled the recipient of the award to participate in the value of Fulgent LLC only to the extent it appreciated from and after the grant date of the award; and (v) prior to the Reorganization, Fulgent LLC was managed by its Manager, Ming Hsieh, who was also Fulgent LLC’s controlling equity holder. In the Reorganization, each outstanding 7.6 units of Fulgent LLC were cancelled in exchange for one share of the Company’s common stock, such that (i) all outstanding Class D common units of Fulgent LLC (including profits interests) were cancelled in exchange for an aggregate of 4,059,900 shares of the Company’s common stock; (ii) all outstanding Class D-1 preferred units of Fulgent LLC were cancelled in exchange for an aggregate of 6,760,733 shares of the Company’s common stock; (iii) all outstanding Class D-2 preferred units were cancelled in exchange for an aggregate of 2,025,623 shares of the Company’s common stock; (iv) all outstanding options to acquire common units of Fulgent LLC were cancelled in exchange for equivalent options to acquire up to an aggregate of 591,112 shares of the Company’s common stock, and all such options became immediately exercisable to the extent vested; and (v) all outstanding restricted share units relating to common units of Fulgent LLC were cancelled in exchange for equivalent restricted stock units (these restricted share units and restricted stock units are both referred to as “RSUs”) relating to 65,789 shares of the Company’s common stock. The Reorganization was accounted for as a common control transaction and no gain or loss was recorded.

Discontinued Operations

The Company historically conducted two lines of business: the Diagnostics business, which the Company conducted directly and which is the only business it is presently pursuing, and its former pharmaceutical business (the “Pharma business”), which was conducted by the Company’s former wholly owned subsidiary, Fulgent Pharma LLC (“Fulgent Pharma”). In addition, Fulgent LLC’s equity interests were separated into two series based on these two lines of business, with the holders of Fulgent LLC’s Class D preferred units and Class D voting and non-voting common units (collectively, the “Class D units”) having economic rights based on the Diagnostics business, and the holders of Fulgent LLC’s Class P preferred units and Class P voting and non-voting common units (collectively, the “Class P units”) having economic rights based on the Pharma business. These Class D units and Class P units were intended to “track,” or reflect, the relative performance of the Diagnostics business and the Pharma business, respectively.

In April 2016, Fulgent LLC’s Operating Agreement was amended and restated to provide for the distribution of Fulgent Pharma in full redemption and cancellation of the Class P units. On April 4, 2016, Fulgent LLC completed the split-off of Fulgent Pharma and the Pharma business by redeeming all of the then-outstanding Class P units and distributing to each holder of Class P units substantially identical shares of Fulgent Pharma and causing Fulgent Pharma to assume all then-outstanding options to purchase Class P units. All Class P units were immediately cancelled upon redemption. The split-off of the Pharma business was a pro-rata distribution to all of the holders of Class P units, but did not involve the holders of Fulgent LLC’s Class D units. The Manager and controlling equity holder of Fulgent LLC prior to the Reorganization, Mr. Hsieh, is the Manager and controlling equity holder of Fulgent Pharma. As a result, the split-off of the Pharma business was accounted for as a common control transaction and the recorded amount of Fulgent Pharma’s net assets was transferred to the holders of Class P units and no gain or loss was recorded.

The financial condition and results of the Pharma business were included in the accompanying consolidated financial statements as discontinued operations for all periods presented. The Class P common and preferred units had the right to participate in earnings and distributions of Fulgent Pharma but were not obligated to fund losses. As a result, in periods of Pharma business net loss, losses were allocated to the holders of Class P common units subject to profits interest thresholds, as they were determined to be the most subordinate unit.

The split-off of the Pharma business is presented as discontinued operations in the accompanying consolidated financial statements for all periods presented.

There were no amounts recorded from discontinued operations in the accompanying consolidated statement of operations for the year ended December 31, 2017.The major components of statements of operations data comprising the income from discontinued operations for the year ended December 31, 2016 are as follows:

	Year Ended December 31,
	2016
	(in thousands)
Operating expenses:
Research and development	$	350
General and administrative		9
Total operating expenses		359
Operating loss		(359	)
Other income		400
Income	$	41

Initial Public Offering

On October 4, 2016, the Company completed the initial public offering of its common stock (the “IPO”), in which it issued and sold an aggregate of 4,830,000 shares of common stock (including 630,000 shares issued and sold on October 7, 2016 pursuant to the underwriters’ exercise in full of their option to purchase additional shares) at a public offering price of $9.00 per share. The Company received net proceeds of approximately $36.0 million, after deducting underwriting discounts and commissions of $3.0 million and other offering expenses paid or payable by the Company of approximately $4.4 million. The shares issued and sold in the IPO were registered under the Securities Act of 1933, as amended, on a registration statement on Form S-1 (File No. 333- 213469), as amended.

Summarized Financial Information of Equity Method Investment Misstatement

Subsequent to the issuance of its condensed consolidated financial statements for the quarter ended June 30, 2017, the Company identified an error in its disclosures of summarized financial information of its equity method investment. Investee leasehold improvements and deposits on equipment, which are non-current assets, were incorrectly reported in such financial statements as current assets in the summarized balance sheet disclosures as of December 31, 2016 and June 30, 2017. Accordingly, the Company has restated the December 31, 2016 summarized financial information in these consolidated financial statements to correct this misstatement, which resulted in the reclassification of $2,810,000 of current assets to non-current assets. The Company evaluated the materiality of this misstatement from quantitative and qualitative perspectives and concluded that it was immaterial to the periods.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2. Summary of Significant Accounting Policies

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments, assumptions and decisions that affect the reported amounts and related disclosures, including the selection of appropriate accounting policies and the assumptions on which to base accounting estimates. In making these estimates and assumptions and reaching these decisions, the Company applies judgment based on its understanding and analysis of the relevant circumstances, including historical data and experience available at the date of the accompanying consolidated financial statements, as well as various other factors management believes to be reasonable under the circumstances. Actual results could differ from these estimates.

On an on-going basis, management evaluates its estimates, primarily those related to: (i) revenue recognition criteria, (ii) accounts receivable and allowances for doubtful accounts, (iii) the useful lives of fixed assets, (iv) estimates of tax liabilities and (v) the valuation of equity-based awards.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents include cash held in banks and money market accounts. Cash equivalents are stated at fair value.

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable are stated at the amount the Company expects to collect. The Company performs credit evaluations of its customers and generally does not require collateral. The Company establishes an allowance for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information that assists in management’s evaluation. The Company writes off accounts receivable following a review by management and a determination that the receivable is uncollectible.

A roll-forward of the activity in the Company’s allowance for doubtful accounts is as follows:

	December 31,
	2017			2016
	(in thousands)
Allowance for doubtful accounts at beginning of year	$	151		$	75
Bad debt expense		160			103
Deductions		(24	)		(27	)
Allowance for doubtful accounts at end of year	$	287		$	151

Marketable Securities

All marketable securities, which consist of debt securities, have been classified as “available for sale” and are carried at fair value. Unrealized gains and losses, net of any related tax effects, are excluded from earnings and are included in other comprehensive loss and reported as a separate component of stockholders’ equity until realized. Realized gains and losses and declines in value judged to be other than temporary, if any, on marketable securities are included in other income (expense), net. The cost of any marketable securities sold is based on the specific-identification method. The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity. Interest on marketable securities is included in interest income. In accordance with the Company’s investment policy, management invests to diversify credit risk and only invests in securities with high credit quality, including U.S. government securities.

The Company regularly evaluates whether declines in the fair value of its investments below their cost are other than temporary. The evaluation includes consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities, and whether it is more likely than not that the Company will be required to sell the securities before the recovery of their amortized cost basis. If the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other than temporary, the Company would reduce the carrying value of the security it holds and record a loss for the amount of such decline. The Company has not recorded any realized losses or declines in value judged to be other than temporary on its investments.

Fair Value of Financial Instruments

The Company's financial instruments consist principally of cash and cash equivalents, marketable securities, accounts receivable and accounts payable. The carrying amounts of certain of these financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, approximate fair value due to their short maturities. Fair value of marketable securities is disclosed in Note 4, Fair Value Measurements, to the accompanying consolidated financial statements.

Concentrations of Credit Risk, Customers and Suppliers

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, accounts receivable and marketable securities, which consist of debt securities, and cash equivalents. As of December 31, 2017, substantially all of the Company’s cash and cash equivalents were deposited in accounts at financial institutions, and amounts may exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which its cash and cash equivalents are held.

In certain periods, a small number of customers has accounted for a significant portion of the Company’s revenue. Three customers comprised 14%, 12% and 10%, respectively, of total revenue in the year ended December 31, 2017, and one such customer comprised 15% of total revenue in the year ended December 31, 2016. One customer comprised 13% of total accounts receivable in the year ended December 31, 2017, and four customers comprised 12%, 11%, 12% and 11%, respectively, of total accounts receivable in the year ended December 31, 2016, of which the latter two customers represent one customer for concentration disclosure purposes as they are managed by the same foreign governmental body.

Revenue from the U.S. government was less than 10% of total revenue in each of the years ended December 31, 2017 and 2016.

The Company relies on a limited number of suppliers for certain laboratory substances used in the chemical reactions incorporated into its processes, referred to as reagents, as well as for the sequencers and various other equipment and materials it uses in its laboratory operations. In particular, the Company relies on a sole supplier for the next generation sequencers and associated reagents it uses to perform its genetic tests and as the sole provider of maintenance and repair services for these sequencers. The Company’s laboratory operations would be interrupted if it encounters delays or difficulties securing these reagents, sequencers, other equipment or materials or maintenance and repair services, which could occur for a variety of reasons, including if the Company needs a replacement or temporary substitute for any of its limited or sole suppliers and is not able to locate and make arrangements with an acceptable replacement or temporary substitute. The Company believes there are currently only a few other manufacturers that are capable of supplying and servicing some of the equipment and other materials necessary for its laboratory operations, including sequencers and various associated reagents.

Equity Method Investments

The Company uses the equity method to account for investments in entities that it does not control, but in which it has the ability to exercise significant influence over operating and financial policies. The Company's proportionate share of the net income or loss of these companies is included in consolidated net earnings. Judgments regarding the level of influence over each equity method investment include consideration of key factors such as the Company's ownership interest, representation on the board of directors or other management body and participation in policy-making decisions.

Fixed Assets

Fixed assets are recorded at cost, net of accumulated depreciation and amortization. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets, which is generally between three and five years. Leasehold improvements are capitalized and amortized over the shorter of their expected lives or the applicable lease term, including renewal options, if available. Major replacements and improvements are capitalized, while general repairs and maintenance are expensed as incurred.

Software for Internal Use

The Company capitalizes certain costs incurred to purchase computer software for internal use. These costs include purchased software packages for Company use. Capitalized computer software costs are amortized over the estimated useful life of the computer software, which is generally three years. Internally developed software costs are capitalized after management has committed to funding the project, it is probable that the project will be completed and the software will be used for its intended function. Costs that do not meet that criteria and costs incurred on projects in the preliminary and post-implementation phases are expensed as incurred.

Impairment of Long-Lived Assets

The Company evaluates the carrying amount of its long-lived assets whenever events or changes in circumstances indicate that the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of an asset and its eventual disposition is less than the carrying amount of the asset. To date, there have been no such impairment losses.

Reporting Segment and Geographic Information

Reporting segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company’s chief operating decision maker is its Chief Executive Officer. The Company views its operations and manages its business in one reporting segment.

Revenue Recognition

The Company generates revenue from sales of its genetic tests. The Company currently receives payments from: hospitals and medical institutions with which it has direct-bill relationships; research institutions; individual patients and third-party payors.

The Company recognizes revenue when all of the following criteria are met: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the fee is fixed or determinable and (iv) collectability is reasonably assured. Criterion (i) is satisfied when the Company has an arrangement or contract in place. Criterion (ii) is satisfied when the Company delivers a report to the ordering physician or test results to the research institution. Determination of criteria (iii) and (iv) are based on management’s judgments regarding whether the fee is fixed or determinable, and whether the collectability of the fee is reasonably assured. The Company recognizes revenue on a cash basis when it cannot conclude that either criterion (iii) or (iv) has been met.

The Company’s test results are delivered electronically, and as such there are no shipping and handling fees incurred by it or billed to customers. The Company’s sales are typically exempt from state sales taxation due to the nature of the results delivered. As a result, the Company currently does not charge customers state sales tax and continues to assess.

Deferred Revenue

Payments received in advance of services rendered are recorded as deferred revenue and are subsequently recognized as revenue in the period in which the applicable revenue recognition criteria, as described above, are met. Deferred revenue consists primarily of revenue from tests performed for customers that have a limited time period following an initial order to request certain follow-up tests at no additional charge.

Overhead Expenses

The Company allocates overhead expenses, such as rent and utilities, to cost of revenue and operating expense categories based on headcount. As a result, an overhead expense allocation is reflected in cost of revenue and each operating expense category.

Cost of Revenue

Cost of revenue reflects the aggregate costs incurred in delivering test results and consists of: personnel costs, including salaries, employee benefit costs, bonuses and equity-based compensation expenses; costs of laboratory supplies; depreciation of laboratory equipment; amortization of leasehold improvements and allocated overhead. Costs associated with performing tests are recorded as tests are processed.

Research and Development Expenses

Research and development expenses represent costs incurred to develop the Company’s technology and future tests. These costs consist of: personnel costs, including salaries, employee benefit costs, bonuses and equity-based compensation expenses; laboratory supplies; consulting costs and allocated overhead. The Company expenses all research and development costs in the periods in which they are incurred.

Selling and Marketing Expenses

Selling and marketing expenses consist of: personnel costs, including salaries, employee benefit costs, bonuses and equity-based compensation expenses; customer service expenses; direct marketing expenses; educational and promotional expenses; market research and analysis and allocated overhead. The Company expenses all selling and marketing costs as incurred.

General and Administrative Expenses

General and administrative expenses include executive, finance and accounting, legal and human resources functions. These expenses consist of: personnel costs, including salaries, employee benefit costs, bonuses and equity-based compensation expenses; audit and legal expenses; consulting costs and allocated overhead. The Company expenses all general and administrative expenses as incurred.

Income Taxes

Income taxes are accounted for under the asset and liability method. The Company provides for federal, state and foreign income taxes currently payable, as well as for taxes deferred due to timing differences between reporting income and expenses for financial statement purposes versus tax purposes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in income tax rates is recognized as income or expense in the period that includes the enactment date.

The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount with a greater than 50% likelihood of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. For income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in its consolidated financial statements. The Company records interest and penalties related to uncertain tax positions, if applicable, as a component of income tax expense.

The Company’s predecessor, Fulgent LLC, is organized as a limited liability company and its members elected to have Fulgent LLC treated as a partnership for income tax purposes. As a result, for all periods prior to the Reorganization, all taxable income or loss and tax credits of the Company generally were reflected in the personal income tax returns of Fulgent LLC’s members, and no provision for federal and state income taxes was provided in the accompanying consolidated financial statements. The Company became a taxable entity upon completion of the Reorganization on September 30, 2016.

Equity-Based Compensation

The Company grants various types of equity-based awards to its employees, consultants and non-employee directors. Equity-based compensation costs are reflected in the accompanying statements of operations based upon each award recipient’s role with the Company. The Company grants to its employees option and RSU awards that generally vest over a specified period of time upon the satisfaction of service-based conditions. Before the Reorganization, the Company also granted to its employees awards of units and profits interests that generally were fully vested at grant. The Company measures compensation expense for equity-based awards granted to employees based on the fair value of the award on the grant date of the award. The Company measures the fair value of option awards using the Black-Scholes option valuation model, the Company measures the fair value of RSU awards based on the fair value of the underlying shares of common stock on the grant date of the award, the Company measured the fair value of unit awards granted before the Reorganization based on the fair value of the units on the grant date of the award, and the Company measured the fair value of profits interest awards granted before the Reorganization using the Black-Scholes option-valuation model.

Compensation expense for employee option awards with a service-based vesting condition is recognized over the vesting period of the award using the accelerated attribution method. Compensation expense for employee RSU awards with a service-based vesting condition is recognized ratably over the vesting period of the award. Compensation expense for employee equity-based awards with both performance-based and service-based vesting conditions is recognized over the period required to satisfy both conditions using the accelerated attribution method.

Transactions with non-employees in which goods or services are the consideration received for the grant of equity-based awards are accounted for based on the fair value of the consideration received or the fair value of the equity-based award, whichever is more reliably measurable. The measurement date of the fair value of the equity-based award is the earlier of the date on which the counterparty’s performance is complete or the date on which it is probable that performance will occur and the fair value is subject to remeasurement at each reporting date over the term of the award. Compensation expense for non-employee option awards is based on the measurement date fair value of the award and recognized using the accelerated attribution method. Compensation expense for non-employee RSU awards is based on the measurement date fair value of the award and recognized ratably over the requisite vesting period of the award.

Foreign Currency Translation and Foreign Currency Transactions

The Company translates the assets and liabilities of its non-U.S. dollar functional currency subsidiaries into U.S. dollars using exchange rates in effect at the end of each period. Expenses for these subsidiaries are translated using rates that approximate those in effect during the period. Gains and losses from these translations are recognized in foreign currency translation included in other comprehensive income (loss) in the accompanying consolidated statements of stockholders’ equity. The Company’s subsidiaries that use the U.S. dollar as their functional currency remeasure monetary assets and liabilities at exchange rates in effect at the end of each period, and inventories, property and nonmonetary assets and liabilities at historical rates. Gains and losses from these remeasurements were not significant in the year ended December 31, 2017.

Comprehensive Loss

Comprehensive loss is comprised of net loss and other comprehensive loss. Other comprehensive loss consists of unrealized loss on marketable securities. The Company did not have reclassifications from other comprehensive loss to the loss during the year ended December 31, 2017.

Basic and Diluted Net Loss per Share

Basic net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and dilutive common share equivalents outstanding during the period. Because the Company has reported a net loss attributable to common stockholders for all periods presented, diluted net loss per common share is the same as basic net loss per common share for these periods.

Emerging Growth Company

Pursuant to the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), a company constituting an “emerging growth company” is, among other things, entitled to rely upon certain reduced reporting requirements. The Company is an emerging growth company, but has irrevocably elected not to take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. As a result, the Company will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for public companies that are not emerging growth companies.

Recent Accounting Pronouncements

ASU No. 2014-09

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which outlines a comprehensive new revenue recognition model designed to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606)–Principal versus Agent Considerations (Reporting Revenue Gross versus Net), which further clarifies the implementation guidance on principal versus agent considerations contained in ASU 2014-09. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606)–Identifying Performance Obligations and Licensing, which further clarifies the implementation guidance relating to identifying performance obligations and the licensing implementation guidance. In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606)–Narrow-Scope Improvements and Practical Expedients, which further clarifies guidance on collectability, noncash consideration, presentation of sales tax, practical expedients and transition. In December 2016, the FASB issued ASU No. 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers, which makes minor corrections or minor improvements to the codification that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. These standards, pursuant to ASU No. 2015-14, Revenue from Contracts with Customers–Deferral of the Effective Date (Topic 606) issued by the FASB in August 2015, will be effective for annual periods (including interim periods) beginning after December 15, 2017. The standard can be applied either retrospectively to each period presented or as a cumulative effect adjustment as of the date of adoption. The Company plans to implement these standards effective January 1, 2018 based on the modified retrospective method.

In the third and fourth quarters of 2017, the Company performed an analysis of the impact of the new revenue recognition standard described in the preceding paragraph, which included a review of existing contracts with customers, an evaluation of the specific terms of such contracts and their appropriate treatment under the new standard, and a comparison of such new treatment to the Company’s then-existing accounting policies to identify differences.

The Company has completed this analysis, and has substantially completed its new revenue recognition accounting policy documentation reflecting the new standard. The Company is also in the process of preparing the transition adjustment that will be reflected in its condensed consolidated financial statements for the quarter ending March 31, 2018. As a result of these analyses and preparations, the Company has identified the following differences between the new standard and the Company’s revenue recognition policy utilized in the periods covered by these financial statements and all prior periods:

•

The Company currently recognizes revenue from third-party payors on a cash basis. Under the new revenue recognition standard, the Company expects to recognize revenue from third-party payors on an accrual basis at the time of delivery of genetic test results to these customers. This will result in the Company’s recognition of revenue from these parties under the new standard earlier than it recognized revenue from these parties under the Company's prior revenue recognition.

•

Upon adopting the new standard on January 1, 2018, the Company will record an adjustment of $327,000 to beginning accumulated deficit and accounts receivable, to reflect genetic tests previously delivered to third-party payors for which revenue was not recognized as of such date.

The Company has evaluated the new disclosure requirements, including any necessary changes to business processes, systems, and controls to support the additional required disclosures.

ASU No. 2016-01

In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, which addresses certain aspects of recognition, measurement, presentation, and disclosure of financial instruments, including a provision that requires equity investments (except for investments accounted for under the equity method of accounting) to be measured at fair value, with changes in fair value recognized in current earnings. The ASU is effective for the Company in the first quarter of 2018, with early adoption permitted. The Company is currently evaluating the effect this ASU will have on its consolidated financial statements and related disclosures.

ASU No. 2016-02

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The update is aimed at making leasing activities more transparent and comparable, and requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. This guidance will become effective for interim and annual reporting periods beginning with the year ending December 31, 2019. The standard requires the use of a modified retrospective transition approach for existing leases. Early adoption is permitted. The Company is currently evaluating the effect this ASU will have on its consolidated financial statements and related disclosures.

ASU No. 2016-13

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments. ASU No. 2016-13 replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses. The update is intended to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The standard will be effective for annual reporting periods beginning after December 15, 2019, including interim periods within those reporting periods. Early adoption is permitted. The Company has not yet evaluated the effect this ASU will have on its consolidated financial statements and related disclosures.

ASU No. 2016-15

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230). The standard clarifies the way certain cash receipts and cash payments are classified with the objective of reducing the existing diversity in practice. The standard is effective for fiscal years and interim periods beginning after December 15, 2017. Early adoption is permitted for all periods beginning after December 15, 2016. The Company is currently evaluating the effect this ASU will have on its consolidated financial statements and related disclosures.

ASU No. 2017-08

In March 2017, the FASB issued ASU No. 2017-08, Receivables–Nonrefundable Fees and Other Costs (Subtopic 310-20). Under the ASU, entities must amortize to the earliest call date the premium on certain purchased callable debt securities. The ASU does not require any accounting change for debt securities held at a discount. The guidance calls for a modified retrospective transition approach under which a cumulative-effect adjustment will be made to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. The ASU is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including in an interim period. The Company has not yet evaluated the effect this ASU will have on its consolidated financial statements and related disclosures.

ASU No. 2018-02

In February 2018, the FASB issued ASU No. 2018-02, Income Statement–Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act enacted by the U.S. federal government on December 22, 2017 (the “2017 Tax Act”). Consequently, the amendments eliminate the stranded tax effects resulting from the 2017 Tax Act and will improve the usefulness of information reported to financial statement users. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period, (1) for public business entities for reporting periods for which financial statements have not yet been issued and (2) for all other entities for reporting periods for which financial statements have not yet been made available for issuance. The Company is currently evaluating the effect this ASU will have on its consolidated financial statements and related disclosures.

Marketable Securities

12 Months Ended

Dec. 31, 2017

Investments Debt And Equity Securities [Abstract]

Marketable Securities

Note 3. Marketable Securities

The Company’s marketable securities consisted of the following:

	December 31, 2017
	Amortized Cost Basis			Unrealized Gains		Unrealized Losses			Aggregate Fair Value
	(in thousands)
Marketable securities:
Short-term
Money market accounts	$	723		$	—	$	—		$	723
Corporate debt securities		20,040			2		(48	)		19,994
Less: Cash equivalents		(723	)		—		—			(723	)
Total short-term marketable securities		20,040			2		(48	)		19,994
Corporate debt securities		14,999			—		(116	)		14,883
Total long-term marketable securities		14,999			—		(116	)		14,883
	$	35,039		$	2	$	(164	)	$	34,877

	December 31, 2016
	Amortized Cost Basis			Unrealized Gains		Unrealized Losses			Aggregate Fair Value
	(in thousands)
Marketable securities:
Short-term
Money market accounts	$	1,580		$	—	$	—		$	1,580
Corporate debt securities		12,988			—		(17	)		12,971
Less: Cash equivalents		(1,580	)		—		—			(1,580	)
Total short-term marketable securities		12,988			—		(17	)		12,971
Corporate debt securities		25,740			3		(146	)		25,597
Total long-term marketable securities		25,740			3		(146	)		25,597
	$	38,728		$	3	$	(163	)	$	38,568

As of December 31, 2017 and 2016, the contractual maturities of the Company’s marketable securities less than one year were $20.0 million and $13.0 million, respectively, and the contractual maturities of the Company’s marketable securities greater than one year and less than five years were $14.9 million and $25.6 million, respectively. Management determined that the gross unrealized losses of $164,000 on the Company’s marketable securities as of December 31, 2017 were temporary in nature. Gross unrealized losses on the Company’s marketable securities were $163,000 as of December 31, 2016. The Company currently does not intend to sell these securities prior to maturity and does not consider these investments to be other-than-temporarily impaired as of December 31, 2017.

Fair Value Measurements

12 Months Ended

Dec. 31, 2017

Fair Value Disclosures [Abstract]

Fair Value Measurements

Note 4. Fair Value Measurements

The authoritative guidance on fair value measurements establishes a framework with respect to measuring assets and liabilities at fair value on a recurring basis and non-recurring basis. Under the framework, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants, as of the measurement date. The framework also establishes a three-tier hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability and are developed based on the best information available in the circumstances. The hierarchy consists of the following three levels:

Level 1:

Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the

reporting entity can access at the measurement date.

Level 2:

Inputs are inputs other than quoted prices included within Level 1 that are observable for the

asset or liability, either directly or indirectly.

Level 3:

Inputs are unobservable inputs for the asset or liability.

The following tables present information about the Company’s financial assets measured at fair value on a recurring basis, based on the three-tier fair value hierarchy:

	December 31, 2017
	Total		Level 1		Level 2		Level 3
	(in thousands)
Marketable securities:
Corporate debt securities	$	34,877	$	—	$	34,877	$	—
Money market accounts		723		723		—		—
Total marketable securities	$	35,600	$	723	$	34,877	$	—

	December 31, 2016
	Total		Level 1		Level 2		Level 3
	(in thousands)
Marketable securities:
Corporate debt securities	$	38,568	$	—	$	38,568	$	—
Money market accounts		1,580		1,580		—		—
Total marketable securities	$	40,148	$	1,580	$	38,568	$	—

The Company’s Level 1 assets include money market instruments and are valued based upon observable market prices. Level 2 assets consist of marketable investment securities consisting of corporate bonds. Level 2 securities are valued based upon observable inputs that include reported trades, broker/dealer quotes, bids and offers. As of December 31, 2017 and 2016, the Company had no investments that were measured using unobservable (Level 3) inputs.

There were no transfers between fair value measurement levels during the years ended December 31, 2017 and 2016.

Gross unrealized gains or losses for cash equivalents and marketable securities as of December 31, 2017 were not material. As of December 31, 2017, unrealized losses for securities in an unrealized loss position for more than 12 months were $107,000. During the years ended December 31, 2016 and 2017, the Company did not recognize other-than-temporary impairment losses related to its marketable securities.

Fixed Assets

12 Months Ended

Dec. 31, 2017

Property Plant And Equipment [Abstract]

Fixed Assets

Note 5. Fixed Assets

Major classes of fixed assets consisted of the following:

		December 31,
	Useful Lives	2017			2016
		(in thousands)
Computer hardware	3 Years	$	1,435		$	1,293
Computer software	3 Years		463			354
Machinery and equipment	5 Years		—			177
Medical lab equipment	5 Years		7,145			4,678
General equipment	3 Years		—			59
Furniture and fixtures	5 Years		159			86
Leasehold improvements	Shorter of lease term or estimated useful life		763			520
Assets not yet placed in service			1,074			1,114
Total			11,039			8,281
Less: Accumulated depreciation			(3,767	)		(2,047	)
Property and equipment, net		$	7,272		$	6,234

Depreciation expense on fixed assets totaled $1.7 million and $1.2 million for the years ended December 31, 2017 and 2016, respectively.

Other Current Assets

12 Months Ended

Dec. 31, 2017

Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]

Other Current Assets

Note 6. Other Current Assets

Other current assets consisted of the following:

	December 31,
	2017		2016
	(in thousands)
Reagents	$	231	$	322
Prepaid expenses		624		375
Prepaid income taxes		1,313		—
Marketable securities interest receivable		204		209
Other receivable		66		—
Total	$	2,438	$	906

Reagents are used for DNA sequencing applications in the Company’s DNA sequencing equipment.

Reporting Segment and Geographic Information

12 Months Ended

Dec. 31, 2017

Segment Reporting [Abstract]

Reporting Segment and Geographic Information

Note 7. Reporting Segment and Geographic Information

The Company views its operations and manages its business in one reporting segment. All long-lived assets were located in the United States during the years ended December 31, 2017 and 2016. Revenue by region was as follows:

	December 31,
	2017		2016
	(in thousands)
Revenue:
United States	$	9,024	$	8,258
Foreign:
Canada		4,091		3,798
People's Republic of China ("PRC")		2,614		3,241
Other Countries		3,001		2,979
Total	$	18,730	$	18,276

Commitments and Contingencies

12 Months Ended

Dec. 31, 2017

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 8. Commitments and Contingencies

Operating Leases

The Company has commitments under various non-cancelable operating leases with varying terms through January 2023. The Company has options to renew some of these leases for three years after their expiration. Future minimum payments under non-cancelable operating leases as of December 31, 2017 are as follows:

	Amounts
Year ending December 31,	(in thousands)
2018	$	254
2019		181
2020		178
2021		165
Thereafter		134
Total minimum lease payments	$	912

The Company’s headquarters is located in Temple City, California, which is comprised of various corporate offices and a laboratory certified under the Clinical Laboratory Improvement Amendments of 1988 (“CLIA”), accredited by the College of American Pathologists (“CAP”) and licensed by the State of California Department of Public Health (“CA DPH”). Additional offices are located in El Monte, California and Atlanta, Georgia and are used for certain research and development, customer service, report generation and other administrative activities.

Rent expense for the years ended December 31, 2017 and 2016 was approximately $250,000, and $204,000, respectively.

On January 31, 2018, we entered into a lease renewal of our headquarters in Temple City, California, which commenced on February 1, 2018 and expires January 31, 2021. The total annual rent under the lease is approximately $269,000.

FF Gene Biotech

See Note 15 for a description of the Company’s commitments related to its joint venture, FF Gene Biotech (as defined in Note 15).

Purchase Obligations

As of December 31, 2017, the Company had purchase obligations of $1.7 million for reagents and equipment.

Contingencies

From time to time, the Company may be subject to legal proceedings and claims arising in the ordinary course of business. Management does not believe that the outcome of any of these matters will have a material effect on the Company’s consolidated financial position, results of operations or cash flows.

Stockholders’/Members’ Equity

12 Months Ended

Dec. 31, 2017

Equity [Abstract]

Stockholders’/Members’ Equity

Note 9. Stockholders’/Members’ Equity

Components of Comprehensive Income (Loss)

Comprehensive income (loss) consists of two components: net income (loss), and other comprehensive income (loss) (“OCI”). OCI refers to revenue, expenses, gains and losses that, in conformity with U.S. GAAP, are recorded as in the Company’s consolidated statements of stockholders’ equity but are excluded from the Company’s consolidated statements of operations, and as a result, its net income (loss). The Company’s OCI consists of foreign currency translation adjustments from its subsidiaries not using the U.S. dollar as their functional currency and unrealized gains and losses on marketable securities classified as available-for-sale, net of taxes.

The tax effects related to unrealized holding gains (losses) on marketable securities were $37,000 and $58,000 for the years ended December 31, 2017 and 2016, respectively.

Certificate of Incorporation

In accordance with the Company’s amended certificate of incorporation, the Company is authorized to issue 50,000,000 shares of common stock, with a par value of $0.0001 per share, and 1,000,000 shares of preferred stock, with a par value of $0.0001 per share. In May 2017, the Company amended its certificate of incorporation to reduce its authorized shares from 200,000,000 to 50,000,000. Holders of the Company’s common stock are entitled to one vote for each share held on all matters submitted to a vote of its stockholders. Holders of the Company’s common stock have no cumulative voting rights. Further, as of December 31, 2017, holders of the Company’s common stock have no preemptive, conversion, redemption or subscription rights and there are no sinking fund provisions applicable to the Company’s common stock. Upon liquidation, dissolution or winding-up of the Company, holders of the Company’s common stock are entitled to share ratably in all assets remaining after payment of all liabilities and the liquidation preferences of any outstanding shares of preferred stock. Subject to preferences that may be applicable to any outstanding shares of preferred stock, holders of the Company’s common stock are entitled to receive dividends, if any, as may be declared from time to time by the Company’s board of directors. As of December 31, 2017, there were no outstanding shares of preferred stock.

Reorganization

Upon completion of the Reorganization on September 30, 2016, all of Fulgent LLC’s outstanding units were cancelled in exchange for shares of the Company’s common stock, at a ratio of 7.6 units of Fulgent LLC cancelled in exchange for each one share of the Company’s common stock.

The following is a summary of the units of Fulgent LLC that were cancelled in exchange for shares of the Company’s common stock:

	Pre-Reorganization
	(in thousands)
Class D-1 preferred units		51,382
Class D-2 preferred units		15,395
Class D common units		2,500
Class D common units — profits interests		28,355
Total		97,632

The units set forth in the table above were cancelled in exchange for an aggregate of 12,846,256 shares of the Company’s common stock. The members’ equity balance of $72.0 million was reclassified into common stock and additional paid-in capital in the accompanying consolidated balance sheet as of December 31, 2016.

Distributions

In the year ended December 31, 2016, the Company made distributions as follows: (i) the Company paid $1.3 million in tax distributions to the former members of Fulgent LLC based on the income tax liabilities of such former members attributable to Fulgent LLC’s 2016 net taxable income through the date of the Reorganization, and (ii) the Company paid $4.6 million to Mr. Hsieh in his capacity as a member of Fulgent LLC as a return of capital contribution. The Company made no distributions in the year ended December 31, 2017.

Xi Long Financing

In May 2016, Fulgent LLC completed a transaction with Xi Long USA, Inc. (“Xi Long”), an independent investor, and certain members of Fulgent LLC. In this transaction, (i) Xi Long acquired 4,618,421 Class D-1 preferred units and 5,644,737 Class D common units from certain existing members of Fulgent LLC for an aggregate purchase price of $12.0 million, which units were required to be redeemed by Fulgent LLC in exchange for its issuance to Xi Long of an equivalent number of Class D-2 preferred units, and (ii) Fulgent LLC sold an additional 5,131,579 Class D-2 preferred units to Xi Long for gross proceeds of $15.2 million. Fulgent LLC incurred issuance costs of $185,000 for the transaction, resulting in net proceeds to Fulgent LLC of $15.0 million. Fulgent LLC immediately cancelled the redeemed Class D common and Class D-1 preferred units upon completion of the transaction. All Class D-2 preferred units issued to Xi Long in the transaction were converted into an aggregate of 2,025,623 shares of the Company’s common stock upon completion of the Reorganization.

This transaction was accounted for as: (i) the retirement of the redeemed Class D common units, (ii) the extinguishment of the redeemed Class D-1 preferred units, with the excess of the consideration transferred over the related carrying amount recorded as a deemed dividend in the amount of $3.7 million, and (iii) the issuance of 15,394,737 Class D-2 preferred units for $32.6 million. As a result of the transaction, Xi Long acquired an aggregate of 15,394,737 Class D-2 preferred units for an aggregate purchase price of $27.2 million, even though, at issuance, the fair value of 15,394,737 Class D-2 preferred units as evidenced by Fulgent LLC’s then most recent third-party valuation was $32.6 million. The $5.5 million difference between the fair value of, and the aggregate consideration paid by Xi Long for, the Class D-2 preferred units issued in the transaction was not attributable to any stated rights or privileges. Rather, Fulgent LLC, Xi Long and the members of Fulgent LLC that were party to the transaction determined to complete the transaction in line with their discussions, notwithstanding that the fair value of the Class D-2 preferred units as evidenced by Fulgent LLC’s third-party valuation had increased from the time these discussions were initiated to the time the transaction was completed. The $5.5 million difference was determined to be a cost of completing the transaction with Xi Long and was recorded as an expense in the accompanying consolidated statement of operations.

Equity-Based Compensation

12 Months Ended

Dec. 31, 2017

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Equity-Based Compensation

Note 10. Equity-Based Compensation

Prior to the Reorganization, the Company’s employees and other service providers were granted awards under the Fulgent Therapeutics LLC Amended and Restated 2015 Equity Incentive Plan (the “2015 Plan”), which provided for the issuance of equity-based awards to eligible employees, directors and consultants. These awards generally consisted of options, RSUs and profits interests. Options granted under the 2015 Plan typically vested over four years and expired 10 years from the date of grant, and were not exercisable, whether or not vested, until the earlier of a liquidity event or incorporation, each as defined in the 2015 Plan. Because the options were subject to both a service condition (as set forth in their vesting schedules) and a performance condition (the occurrence of a qualifying liquidity event or incorporation), no equity-based compensation expense was recognized for these options until the performance condition was deemed to have been satisfied, which occurred upon completion of the Reorganization. RSUs granted under the 2015 Plan typically vested over four years. Awards of profits interests were typically fully vested at the date of grant.

In connection with the Reorganization, the Company approved its 2016 Omnibus Incentive Plan (the “2016 Plan”), which provides for the issuance of up to an aggregate of 2,038,480 shares of the Company’s common stock pursuant to awards granted to eligible employees, directors and consultants. As of December 31, 2017, there were 487,826 shares of the Company’s common stock remaining available for grants of future awards under the 2016 Plan. The vesting period, contractual life and other material terms and conditions of awards granted under the 2016 Plan are generally not significantly different from the terms and conditions of awards granted under the 2015 Plan.

At the effective time of the Reorganization:

•

The 2015 Plan was terminated, and no additional awards have since been or will in the future be granted thereunder.

•

Each outstanding option to purchase 7.6 Class D common units of Fulgent LLC was cancelled in exchange for an equivalent option granted under the 2016 Plan to purchase one share of the Company’s common stock. The new options are subject to the same vesting schedule and other material terms and conditions as the cancelled options. The Reorganization was considered an incorporation pursuant to the terms of the 2015 Plan and the performance condition applicable to all options was deemed to have been satisfied. As a result, all of the options became immediately exercisable, to the extent vested, upon completion of the Reorganization. This satisfaction of the performance condition resulted in a cumulative stock-based compensation expense of $1.1 million for the requisite service period, which the Company recorded during the period in which the Reorganization occurred.

•

Each outstanding RSU relating to 7.6 Class D common units of Fulgent LLC was cancelled in exchange for an equivalent RSU granted under the 2016 Plan relating to one share of the Company’s common stock. The new RSUs are subject to the same vesting schedule and other material terms and conditions as the cancelled RSUs.

•

Pursuant to the determination of the Manager of Fulgent LLC, the participation thresholds applicable to all Class D common units that constituted profits interests (i) were ignored and not applied in calculating the number of shares of the Company’s common stock that were issued in exchange for such units in the Reorganization, and (ii) did not carry over to such shares of the Company’s common stock. As a result, the holders of Fulgent LLC’s Class D common units that constituted profits interests received shares of the Company’s common stock in the Reorganization at the same ratio, 7.6-to-one, as the holders of Fulgent LLC’s Class D common units that were not subject to profits interest thresholds. Ignoring all profits interest thresholds upon the conversion of the Class D common units that constitute profits interests into shares of the Company’s common stock resulted in an equity-based compensation expense of $1.4 million that the Company recorded during the period in which the Reorganization occurred.

The Company has included equity-based compensation expense as part of cost of revenue and operating expenses in the accompanying consolidated statements of operations as follows:

	Year Ended December 31,
	2017		2016
	(in thousands)
Cost of revenue	$	479	$	754
Research and development		807		1,161
Selling and marketing		318		454
General and administrative		515		2,285
Total	$	2,119	$	4,654

Award Activity

The below discussions of equity-based award activity, including all nomenclature, share numbers and weighted-average exercise prices, have been adjusted to give retroactive effect to the Reorganization as if it occurred at the beginning of each period presented.

Option Awards

The following table summarizes activity for options to acquire shares of the Company’s common stock in the years ended December 31, 2017 and 2016:

	Number of Units/Shares Subject to Options (in thousands)			Weighted- Average Exercise Price		Weighted- Average Grant Date Fair Value		Weighted- Average Remaining Contractual Life (in years)		Aggregate Intrinsic Value (in thousands) (1)
Balance at December 31, 2015		274		$	0.38				9.8	$	645
Authorized		—
Granted		324		$	1.18	$	7.94
Exercised		—
Canceled		(42	)	$	0.38
Balance at December 31, 2016		556		$	0.85				9.0	$	5,976
Authorized		—
Granted		—
Exercised		(81	)	$	0.38	$	4.19				578
Canceled		(10	)	$	4.91	$	6.32
Balance at December 31, 2017		465		$	0.84				8.0	$	1,785
Exercisable as of December 31, 2017		201		$	0.77				8.0	$	779

(1)	Aggregate intrinsic value is calculated as the difference between (i) the exercise price of options that, as of the applicable date, have an exercise price in excess of the fair value of the Company’s common stock, and (ii) the fair value of the Company’s common stock as of the applicable date.

The Company granted no option awards in the year ended December 31, 2017. The total fair value of options that vested during the years ended December 31, 2017 and 2016 was $1.1 million and $263,000, respectively. As of December 31, 2017, the remaining unrecognized compensation expense related to all outstanding option awards was $505,000 and is expected to be recognized over a weighted-average period of 1.8 years.

Share Awards

In the year ended December 31, 2016, the Company granted one award of 329,000 shares of common stock with a grant date fair value of $1.6 million. These shares were immediately vested upon grant, and as a result, the full fair value of the award was recognized in equity-based compensation expense at the time of grant. The award was not granted under the 2015 Plan or the 2016 Plan.

RSU Awards

RSUs are awards that entitle the holder to receive shares of the Company’s common stock upon satisfaction of vesting conditions. Each RSU represents the contingent right to receive one share of the Company’s common stock upon vesting and settlement.

No RSU awards were granted prior to the year ended December 31, 2016. The following table summarizes activity for RSUs relating to shares of the Company’s common stock in the years ended December 31, 2017 and 2016:

	Number of Shares (in thousands)			Weighted-Average Grant Date Fair Value
Balance at December 31, 2015		—			—
Granted		364		$	9.69
Vested and settled		—
Forfeited		(2	)		9.02
Balance at December 31, 2016		362		$	9.69
Granted		708		$	5.09
Vested and settled		(90	)	$	9.66
Forfeited		(43	)	$	9.33
Balance at December 31, 2017		937		$	7.39

The RSU awards granted in the years ended December 31, 2017 and 2016 will result in aggregate equity-based compensation expense of $4.8 million and $3.5 million, respectively, in each case to be recognized over four years from the grant date of each award granted in the period. As of December 31, 2017, the remaining unrecognized compensation expense related to all outstanding RSU awards was $6.2 million and is expected to be recognized over a weighted-average period of 3.4 years.

Fair Value Assumptions for Option Awards

The Company uses the Black-Scholes option-pricing model to measure the fair value of option awards. The Black-Scholes option-pricing model requires the input of various assumptions, each of which is subjective and requires significant judgment. These assumptions include the following:

•

Expected Term. The expected term represents the period that the Company’s equity-based awards are expected to be outstanding. The Company determines the expected term assumption based on the vesting terms, exercise terms and contractual terms of the options, and, in the case of equity-based awards subject to a profits interest threshold granted before the Reorganization, based on the estimated time to liquidity.

•

Risk-Free Interest Rate. The Company determines the risk-free interest rate by using the equivalent to the expected term based on the U.S. Treasury yield curve in effect as of the date of grant.

•

Dividend Yield. The assumed dividend yield is based on the Company’s expectation that it will not pay dividends in the foreseeable future, which is consistent with its history of not paying dividends.

•

Expected Volatility. The Company does not have sufficient history to estimate the volatility of the price of its common equity or the expected term of its options. The Company calculates expected volatility based on historical volatility data of a representative group of companies that are publicly traded. The Company selected representative companies with comparable characteristics to it, including risk profiles and position within the industry, and with historical equity price information sufficient to meet the expected term of the equity-based awards. The Company computes the historical volatility of this selected group using the daily closing prices for the selected companies’ equity during the equivalent period of the calculated expected term of its equity-based awards. The Company will continue to use the representative group volatility information until the historical volatility of its equity is relevant to measure expected volatility for future option grants.

•

Forfeiture Rate. The Company has early adopted ASU No. 2016-09, Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, and it has elected to account for forfeitures as they occur.

Awards to Employees

The table below sets forth the weighted-average assumptions used in the Black-Scholes option-pricing model to estimate the fair value of options to acquire shares of the Company’s common stock (or, prior to the Reorganization, options to acquire common units of Fulgent LLC) granted to employees during the year ended December 31, 2016. The Company did not grant any options to acquire shares of the Company’s common stock to employees during the year ended December 31, 2017.

	Year Ended December 31,
	2016
Expected term (in years)		6.1
Risk-free interest rates		1.4	%
Dividend yield		—
Expected volatility		95.6	%

Awards to Non-Employees

Equity-based compensation expense for options granted to non-employees is measured based on the fair value of the options because it is more reliably measurable than the fair value of the services received as consideration for the options. Such compensation expense is recognized as the options are earned.

The fair value of non-employee options is re-calculated at each reporting date until the option vests or there is a substantial incentive for the non-employee not to perform the required services.

The table below sets forth the weighted-average assumptions used in the Black-Scholes option-pricing model to estimate the fair value of options to acquire shares of the Company’s common stock (or, prior to the Reorganization, options to acquire common units of Fulgent LLC) granted to non-employees during the years ended December 31, 2016. The Company did not grant any options to acquire shares of the Company’s common stock to non-employees during the year ended December 31, 2017.

	Year Ended December 31,
	2016
Expected term (in years)		10
Risk-free interest rates		1.6	%
Dividend yield		—
Expected volatility		96.9	%

Determination of Fair Value on Grant Dates

For all periods after completion of the IPO on October 4, 2016, the fair value of the shares of the Company’s common stock underlying option and RSU awards is determined by the Company’s board of directors or the compensation committee thereof based on the closing sales price of the Company’s common stock on the date of grant as reported by the Nasdaq Global Market.

For all periods before completion of the Reorganization and the IPO, the fair value of the common units underlying Fulgent LLC’s equity-based awards was estimated on each grant date by Fulgent LLC’s Manager. In determining fair value, the Manager considered valuations prepared by an independent third party in a manner consistent with the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation. In conducting the valuations, Fulgent LLC used a range of assumptions and methodologies and considered all objective and subjective factors it believed to be relevant, including management’s best estimate of Fulgent LLC’s business condition, prospects and operating performance at each valuation date and the following additional factors: the fact that Fulgent LLC was a privately held company with illiquid securities; Fulgent LLC’s stage of commercialization; the likelihood of achieving a liquidity event for Fulgent LLC’s equity, such as an initial public offering, given prevailing market conditions; Fulgent LLC’s historical operating results; valuations of comparable public companies; Fulgent LLC’s discounted future cash flows, based on its projected operating results; and Fulgent LLC’s capital structure, including the rights and preferences of its various classes of equity. These valuations involved significant assumptions, judgments and estimates.

In determining the fair value of Fulgent LLC’s Class D common units related to awards of such units and options to acquire such units granted in 2016 before completion of the Reorganization and the IPO, Fulgent LLC estimated the enterprise value of the business using the option pricing back-solve method within the market approach, which considers the sale price of equity in a recent financing and “backsolves” the equity value using an option-pricing model that gives consideration to a company’s capitalization structure and rights of preferred and common equity holders.

The estimated enterprise value of the business was then allocated to Fulgent LLC’s common units using the probability-weighted expected return method, commonly referred to as PWERM, in which equity is valued based upon the probability-weighted present value of expected future returns considering various future available outcomes and the rights of each class of equity, and applying a marketability discount of 20% due to the illiquidity of the common units prior to completion of the IPO.

Income Taxes

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Income Taxes

Note 11. Income Taxes

Provision for income taxes consists of U.S. federal and state income taxes. A deferred tax liability is recognized for all taxable temporary differences, and a deferred tax asset is recognized for all deductible temporary differences, operating losses and tax credit carryforwards. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.

Prior to the Reorganization, Fulgent LLC was organized as a limited liability company and its members elected to have Fulgent LLC treated as a partnership for income tax purposes. All taxable income or loss and tax credits generally were reflected in the personal income tax returns of the Fulgent LLC’s members. Accordingly, no provision for federal and state income taxes was provided in the accompanying consolidated financial statements prior to the Reorganization. Upon completion of the Reorganization, the Company converted from a pass-through entity for tax purposes to a taxable entity. The change in tax status resulted in $417,000 income tax expense related to the recognition of a net state deferred tax asset of $86,000 and a net federal deferred tax liability of $503,000, which represents the temporary differences in existence on September 30, 2016 between the tax basis of the Company’s assets and liabilities and the amount reported in the financial statements. As of December 31, 2017 and 2016, the net state deferred tax asset was $90,000 and $54,000, respectively, and the net federal deferred tax asset (liability) was $36,000 and $(243,000), respectively.

The 2017 Tax Act, which was signed into law on December 22, 2017, has resulted in significant changes to the U.S. corporate income tax system. These changes include, among others, a federal statutory rate reduction from 35% to 21%, the elimination or reduction of certain domestic deductions and credits and limitations on the deductibility of interest expenses and executive compensation expenses. The 2017 Tax Act also transitions international taxation from a worldwide system to a modified territorial system and includes base erosion prevention measures on non-U.S. earnings. These changes are effective beginning in 2018. The Company accounts for changes in tax rates and tax laws in the period of enactment. As a result, for 2017, due to the reduction in the corporate income tax rate with the enactment of the 2017 Tax Act, the Company recorded a tax expense of $22,000 related to the revaluation of its net deferred tax assets. The Company has determined that the various other provisions of the 2017 Tax Act are not expected to have a material impact on the Company’s results of operations or financial condition, largely because of the amount of the Company’s net operating loss carryover and the Company has no unrepatriated foreign earnings.

Income tax expense (benefit) consisted of the following:

	Year Ended December 31,
	2017			2016
	(in thousands)
Current:
Federal	$	(599	)	$	616
State		(80	)		58
Total Current		(679	)		674
Deferred:
Federal		(300	)		295
State		(36	)		(49	)
Change in valuation allowance		—			—
Total Deferred		(336	)		246
Total income tax expense (benefit)	$	(1,015	)	$	920

Reconciliation of the difference between the federal statutory income tax rate and the effective income tax rate is as follows:

	Year Ended December 31,
	2017			2016

Tax provision at federal statutory rate		34.00	%		34.00	%
State taxes		0.78	%		1.98	%
Other		1.54	%		0.16	%
Impact of tax reform (1)		-0.02	%
Stock based compensation		-2.13	%
Recognition of pre-merger temporary differences					-19.51	%
LLC income not subject to corporate taxes					-37.23	%
Tax provision		34.17	%		-20.60	%
________________
(1) The effective tax rate for the year ended December 31, 2017 includes the Company’s estimate of the effect of the 2017 Tax Act, which primarily relates to the remeasurment of existing deferred taxes as a result of the change to the U.S. federal corporate income tax rate.

The following table summarizes the elements of the deferred tax assets (liabilities):

	Year Ended December 31,
	2017			2016
	(in thousands)
Deferred tax assets
Accrued vacation and other accrued expenses	$	96		$	69
Provision for bad debts		65			54
Net operating losses		148
Stock based compensation		594			603
Unrealized loss on investments		37			58
State income taxes		6			20
Equity Method Investment		118
Gross deferred tax assets		1,064			804
Less: Valuation allowance		(118	)		-
Net deferred tax assets		946			804
Deferred tax liabilities
Depreciation		820			993
Total deferred tax liabilities		820			993
Net deferred tax assets (liabilities)	$	126		$	(189	)

During 2017 the Company recorded a deferred tax asset related to its equity method investment in FF Gene Biotech. When realized, the asset will generate a capital loss which may only be used to offset capital gain income. The Company does not currently have any capital gain income and has therefore recorded a full valuation allowance against this asset.

Uncertain Tax Positions

The Company is subject to income taxation by the United States government and certain states in which the Company's activities give rise to an income tax filing requirement. The Company does not have income tax filing requirements in any foreign jurisdiction, nor are any taxes withheld from income taxes withheld from foreign sales. As of December 31, 2017, there were no pending tax audits in any jurisdiction.

There were no tax-related interest or penalties accrued at December 31, 2017 and 2016.

While the Company believes it has adequately provided for all tax positions, amounts asserted by taxing authorities could differ from the Company's accrued positions. Accordingly, additional provisions on federal, state and foreign tax-related matters could be recorded in future periods as revised estimates are settled or otherwise resolved.

Income (Loss) Per Share

12 Months Ended

Dec. 31, 2017

Earnings Per Share [Abstract]

Income (Loss) per Share

Note 12. Income (Loss) per Share

Income (loss) per share for the years ended December 31, 2017 and 2016 was computed as if the Reorganization had occurred at the beginning of each period presented, with the exception of Class P units, as they are not subject to the Reorganization. The following is a reconciliation of the basic and diluted income (loss) per share computations:

	Years Ended
	2017								2016
	Continuing Operations			Discontinued Operations		Total			Continuing Operations			Discontinued Operations		Total
	(in thousands, except per share data)
Income (loss)	$	(2,510	)	$	—	$	(2,510	)	$	(5,388	)	$	41	$	(5,347	)
Deemed dividend on redemption of Class D-1 preferred units		—			—		—		$	(3,727	)		—	$	(3,727	)
Distribution to Class D-1 preferred unitholder		—			—		—		$	(4,592	)		—	$	(4,592	)
Income (loss) allocable to common stockholders	$	(2,510	)	$	—	$	(2,510	)	$	(13,707	)	$	41	$	(13,666	)
Income (loss) allocated to common stockholders	$	(2,510	)						$	(13,707	)
Income (loss) allocated to Class P common units		—								—			18
Income (loss) allocated to Class P preferred units		—								—			23
Weighted-average common shares - outstanding, basic and diluted		17,739								13,710			—
Weighted-average Class P common units - profits interests - outstanding, basic and diluted													10,123
Weighted-average Class P preferred units - outstanding, basic and diluted													13,238
Income (loss) per Class P common units - profits interests, basic and diluted												$	—
Income (loss) per Class P preferred units, basic and diluted												$	—
Income (loss) per common share from continuing operations, basic and diluted	$	(0.14	)						$	(1.00	)

On April 4, 2016, Fulgent LLC completed the split-off of the Pharma business. The financial condition and results of the Pharma business are included in the accompanying consolidated financial statements as discontinued operations for all periods presented. The split-off of the Pharma business was effected with a pro-rata distribution to all of the holders of Class P units. As a result, on April 4, 2016, Fulgent LLC redeemed all Class P preferred and common units, distributed to each holder of such units substantially identical units of Fulgent Pharma, and caused Fulgent Pharma to assume all then-outstanding options to acquire Class P common units.

The following securities have been excluded from the calculation of diluted income (loss) per share for all periods presented because their effect would have been anti-dilutive:

	Years Ended
	2017		2016
	(in thousands)
Options		464		490
RSUs		526		79

The anti-dilutive shares described above were calculated using the treasury stock method. During the years ended December 31, 2017 and 2016, the Company had outstanding options and RSUs that were excluded from the weighted-average share calculation for continuing operations due to the Company’s net loss positions.

Retirement Plans	12 Months Ended
Retirement Plans	Dec. 31, 2017
Compensation And Retirement Disclosure [Abstract]
Retirement Plans	Note 13. Retirement Plans The Company offers a 401(k) retirement savings plan (the “401(k) Plan”) for its employees, including its executive officers, who satisfy certain eligibility requirements. The Internal Revenue Code of 1986, as amended, allows eligible employees to defer a portion of their compensation, within prescribed limits, on a pre-tax basis through contributions to the 401(k) Plan. The Company matches contributions to the 401(k) Plan based on the amount of salary deferral contributions the participant makes to the 401(k) Plan. The Company will match up to 3% of an employee’s compensation that the employee contributes to his or her 401(k) Plan account. Total Company matching contributions to the 401(k) Plan were $108,000 and $86,000 in the years ended December 31, 2017 and 2016, respectively.

Related Party	12 Months Ended
Related Party	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party	Note 14. Related Party Dr. Yun Yen, who is a member of the Company’s Board of Directors and a stockholder, serves as the President and Chairman of the Board for the Sino-American Cancer Foundation (the “Foundation”) and served as the President for the Taipei Medical University (the “University”), from August 1, 2011 through July 31, 2016 and currently serves as a Chair Professor for the University. From time to time, the Company performs research testing services for the Foundation. The Company recognized zero and $150,000 during the years ended December 31, 2017 and 2016, respectively, as consideration for such services. Additionally, the Company subleases certain of its headquarters facilities to the Foundation. The Company recognized $22,000 and $28,000 in the years ended December 31, 2017 and 2016, respectively, as consideration for such sublease. As of December 31, 2017 and 2016, zero was owed to the Company by the Foundation in connection with these relationships. From time to time, the Company performs genetic sequencing services for the University. The Company recognized $82,600 and $353,000 in the years ended December 31, 2017 and 2016, respectively, as consideration for such services. As of December 31, 2017 and 2016, $40,000 and $29,550, respectively, was owed to the Company by the University in connection with this relationship. As more fully described in Note 15, in April 2017, the Company, through an affiliated company formed for the purpose of the relationship, entered into a cooperation agreement (the “JV Agreement”) with Xilong Scientific Co., Ltd. (“Xilong Scientific”) and Fuzhou Jinqiang Investment Partnership (LP) (“FJIP”) to form a joint venture under the laws of the PRC called Fujian Fujun Gene Biotech Co., Ltd. (“FF Gene Biotech”). Xilong Scientific is an affiliate of Xi Long, which, as of December 31, 2017, owned 11% of the outstanding shares of the Company’s common stock, and FJIP is owned by key management of FF Gene Biotech, including Dr. Han Lin Gao, the Chief Scientific Officer and a large stockholder of the Company and the owner of approximately 25% of FJIP. Fulgent Pharma utilizes space in the facility at which the Company’s laboratory and corporate headquarters are located. Since the completion of the Pharma Split-Off, Fulgent Pharma reimburses the Company for the portion of the rent the Company pays that is attributable to the space used by Fulgent Pharma, which amounts are not significant. As of December 31, 2017 and 2016, $3,000 and zero, respectively, was owed to the Company by Fulgent Pharma as a result of this arrangement, which is recorded in Other receivable in Other current assets in the accompanying consolidated balance sheets.

Equity Method Investments

12 Months Ended

Dec. 31, 2017

Equity Method Investments And Joint Ventures [Abstract]

Equity Method Investments

Note 15. Equity Method Investments

In April 2017, the Company, through an affiliated company formed for the purpose of the relationship, entered into the JV Agreement with Xilong Scientific and FJIP to form FF Gene Biotech, a joint venture formed under the laws of the PRC to offer genetic testing services to customers in the PRC. Pursuant to the terms of the JV Agreement, the Company has agreed to contribute to FF Gene Biotech genetic sequencing and other equipment with a total cost of 60,000,000 renminbi (“RMB”) over a three-year period for a 30% ownership interest in FF Gene Biotech, Xilong Scientific has agreed to contribute to FF Gene Biotech 102,000,000 RMB over a three-year period for a 51% ownership interest in the FF Gene Biotech, and FJIP has agreed to contribute to FF Gene Biotech 19,000,000 RMB over a five-year period for a 19% ownership interest in FF Gene Biotech. The Company’s maximum exposure to fund losses of FF Gene Biotech as a result of its minority ownership of this entity is equal to its contribution obligation under the JV Agreement as described above. As of December 31, 2017, 43,600,000 RMB (or approximately $6.7 million U.S. dollars) remained to be contributed to FF Gene Biotech by the Company under the terms of the JV Agreement, and the Company has purchased and contributed equipment with an aggregate fair value of $2.5 million pursuant to its contribution commitment under the JV Agreement, all of which was contributed in the year ended December 31, 2017. The Company accounted for this contribution in accordance with Accounting Standards Codification 845, Nonmonetary Transactions, and recorded an investment based on the fair value of the contributed equipment, which is the same as carryover basis.

The Company concluded FF Gene Biotech is a variable interest entity as FF Gene Biotech lacks sufficient capital to operate independently. The Company concluded that it alone does not have the power to direct the most significant activities of FF Gene Biotech and therefore is not the primary beneficiary of the entity. Judgment regarding the level of influence over FF Gene Biotech includes consideration of key factors such as the Company's ownership interest, representation on the board of directors or other management body and participation in policy-making decisions.

The Company accounts for its 30% interest in FF Gene Biotech using the equity method of accounting. The Company recorded its proportionate share of the losses of FF Gene Biotech for the year ended December 31, 2017 in the accompanying consolidated statements of operations, and recorded its contribution during the period, net of its proportionate share in the accumulated losses of FF Gene Biotech, in the accompanying consolidated balance sheet as of December 31, 2017.

The Company has entered into a license agreement with FF Gene Biotech, pursuant to which it granted FF Gene Biotech a license to use certain of the Company’s clinical molecular diagnostic gene detection technology and related software and proprietary reference library of genetic information, along with any improvements on this technology the Company may develop during the term of the license agreement. Under the license agreement, FF Gene Biotech will pay to the Company, on a quarterly basis, certain royalties based on the revenues of FF Gene Biotech. The Company earned an insignificant amount of royalties under the license agreement for the year ended December 31, 2017.

In November 2017, FF Gene Biotech invested and formed a majority-owned subsidiary that focuses on sales and marketing for FF Gene Biotech. The financial information of the subsidiary is consolidated in the summarized financial information for FF Gene Biotech disclosed below.

The Company had no equity method investments as of December 31, 2016. Equity method investments as of December 31, 2017 consisted of the following:

	Carrying Value		Ownership Percentage
	(in thousands)
FF Gene Biotech	$	1,937		30	%
Total equity method investments	$	1,937		30	%

Summary Financial Information

Summary financial information for FF Gene Biotech is as follows:

	December 31,
	2017		2016
Consolidated Balance Sheet Data:	(in thousands)
Current Assets	$	2,474	$	830
Non-Current Assets		4,851		4,593
Current Liabilities		942		119
Non-Current Liabilities		—		—
Minority Interest		—		—
Stockholders' Equity		6,383		5,304

	Years Ended December 31,
	2017			2016
Consolidated Statement of Operations Data:	(in thousands)
Net Sales	$	90		$	—
Gross Profit		10			—
Net Loss		(2,318	)		(662	)
Share of loss from investments accounted for using the equity method (1)		(524	)		—

(1) The Company's share of loss is based on pro-rated net loss beginning April 25, 2017, the date on which the Company entered into the JV Agreement.

Selected Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2017

Quarterly Financial Information Disclosure [Abstract]

Selected Quarterly Financial Information (Unaudited)

Note 16. Selected Quarterly Financial Data (Unaudited)

The tables below set forth the Company’s quarterly consolidated statements of operations data for the eight quarters ended December 31, 2017. In the opinion of management, this quarterly data has been prepared on the same basis as the accompanying consolidated financial statements and includes all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the results of operations for the periods presented. See Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the report in which these consolidated financial statements are included for descriptions of the effects of any extraordinary, unusual or infrequently occurring items recognized in any of the periods covered by this data. The results for any one quarter are not indicative of the results to be expected in the current period or any future period.

	Three Months Ended
	Dec. 31, 2017			Sept. 30, 2017			June 30, 2017			Mar. 31, 2017		Dec. 31, 2016		Sept. 30, 2016			June 30, 2016			Mar. 31, 2016
	(dollars in thousands, except per share data)
Statement of Operations Data:
Revenue	$	4,281		$	4,503		$	4,640		$	5,306	$	5,854	$	5,011		$	3,971		$	3,440
Cost of revenue		2,545			2,268			1,879			1,859		1,863		2,143			1,411			1,304
Gross profit		1,736			2,235			2,761			3,447		3,991		2,868			2,560			2,136
Operating expenses:
Research and development		1,324			1,128			920			851		818		1,523			656			561
Selling and marketing		1,080			1,383			851			891		798		893			477			301
General and administrative		1,402			1,205			1,140			1,486		1,116		1,147			457			1,889
Total operating expenses		3,806			3,716			2,911			3,228		2,732		3,563			1,590			2,751
Operating income (loss)		(2,070	)		(1,481	)		(150	)		219		1,259		(695	)		970			(615	)
Interest and other income (expense)		97			145			120			119		57		5			(5,462	)		13
Income (loss) before income taxes and equity loss in investee		(1,973	)		(1,336	)		(30	)		338		1,316		(690	)		(4,492	)		(602	)
Provision for income taxes		(596	)		(415	)		(110	)		106		503		417			-			-
Income (loss) before equity loss in investee		(1,377	)		(921	)		80			232		813		(1,107	)		(4,492	)		(602	)
Equity loss in investee		(247	)		(172	)		(105	)		-		-		-			-			-
Net income (loss)	$	(1,624	)	$	(1,093	)	$	(25	)	$	232	$	813	$	(1,107	)	$	(4,492	)	$	(602	)

Net income (loss) per common share:
Basic	$	(0.09	)	$	(0.06	)	$	-		$	0.01	$	0.05	$	(0.44	)	$	(5.49	)	$	(0.02	)
Diluted	$	(0.09	)	$	(0.06	)	$	-		$	0.01	$	0.05	$	(0.44	)	$	(5.49	)	$	(0.02	)

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Use of Estimates

Principles of Consolidation

Cash and Cash Equivalents

Accounts Receivable and Allowance for Doubtful Accounts

A roll-forward of the activity in the Company’s allowance for doubtful accounts is as follows:

	December 31,
	2017			2016
	(in thousands)
Allowance for doubtful accounts at beginning of year	$	151		$	75
Bad debt expense		160			103
Deductions		(24	)		(27	)
Allowance for doubtful accounts at end of year	$	287		$	151

Marketable Securities

Fair Value of Financial Instruments

Concentrations of Credit Risk, Customers and Suppliers

Revenue from the U.S. government was less than 10% of total revenue in each of the years ended December 31, 2017 and 2016.

Equity Method Investments

Fixed Assets

Software for Internal Use

Impairment of Long-Lived Assets

Reporting Segment and Geographic Information

Research and Development Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Income Taxes

Equity-Based Compensation

Foreign Currency Translation and Foreign Currency Transactions

Comprehensive Loss

Basic and Diluted Net Loss per Share

Emerging Growth Company

Recent Accounting Pronouncements

ASU No. 2014-09

•

The Company has evaluated the new disclosure requirements, including any necessary changes to business processes, systems, and controls to support the additional required disclosures.

ASU No. 2016-01

ASU No. 2016-02

ASU No. 2016-13

ASU No. 2016-15

ASU No. 2017-08

ASU No. 2018-02

Overview and Basis of Presentation (Tables)

12 Months Ended

Dec. 31, 2017

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Major Components of Statements of Operations Data Comprising Income (Loss) from Discontinued Operations

The major components of statements of operations data comprising the income from discontinued operations for the year ended December 31, 2016 are as follows:

	Year Ended December 31,
	2016
	(in thousands)
Operating expenses:
Research and development	$	350
General and administrative		9
Total operating expenses		359
Operating loss		(359	)
Other income		400
Income	$	41

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=84176398&loc=SL51724579-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84176398&loc=d3e2941-110230

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

+ Details

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Roll-Forward of Activity in Allowance for Doubtful Accounts

A roll-forward of the activity in the Company’s allowance for doubtful accounts is as follows:

	December 31,
	2017			2016
	(in thousands)
Allowance for doubtful accounts at beginning of year	$	151		$	75
Bad debt expense		160			103
Deductions		(24	)		(27	)
Allowance for doubtful accounts at end of year	$	287		$	151

Marketable Securities (Tables)

12 Months Ended

Dec. 31, 2017

Investments Debt And Equity Securities [Abstract]

Summary of Marketable Securities

The Company’s marketable securities consisted of the following:

	December 31, 2017
	Amortized Cost Basis			Unrealized Gains		Unrealized Losses			Aggregate Fair Value
	(in thousands)
Marketable securities:
Short-term
Money market accounts	$	723		$	—	$	—		$	723
Corporate debt securities		20,040			2		(48	)		19,994
Less: Cash equivalents		(723	)		—		—			(723	)
Total short-term marketable securities		20,040			2		(48	)		19,994
Corporate debt securities		14,999			—		(116	)		14,883
Total long-term marketable securities		14,999			—		(116	)		14,883
	$	35,039		$	2	$	(164	)	$	34,877

	December 31, 2016
	Amortized Cost Basis			Unrealized Gains		Unrealized Losses			Aggregate Fair Value
	(in thousands)
Marketable securities:
Short-term
Money market accounts	$	1,580		$	—	$	—		$	1,580
Corporate debt securities		12,988			—		(17	)		12,971
Less: Cash equivalents		(1,580	)		—		—			(1,580	)
Total short-term marketable securities		12,988			—		(17	)		12,971
Corporate debt securities		25,740			3		(146	)		25,597
Total long-term marketable securities		25,740			3		(146	)		25,597
	$	38,728		$	3	$	(163	)	$	38,568

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2017

Fair Value Disclosures [Abstract]

Information about Financial Assets Measured at Fair Value on Recurring Basis Based on Three-Tier Fair Value Hierarchy

The following tables present information about the Company’s financial assets measured at fair value on a recurring basis, based on the three-tier fair value hierarchy:

	December 31, 2017
	Total		Level 1		Level 2		Level 3
	(in thousands)
Marketable securities:
Corporate debt securities	$	34,877	$	—	$	34,877	$	—
Money market accounts		723		723		—		—
Total marketable securities	$	35,600	$	723	$	34,877	$	—

	December 31, 2016
	Total		Level 1		Level 2		Level 3
	(in thousands)
Marketable securities:
Corporate debt securities	$	38,568	$	—	$	38,568	$	—
Money market accounts		1,580		1,580		—		—
Total marketable securities	$	40,148	$	1,580	$	38,568	$	—

Fixed Assets (Tables)

12 Months Ended

Dec. 31, 2017

Property Plant And Equipment [Abstract]

Major Classes of Fixed Assets

Major classes of fixed assets consisted of the following:

		December 31,
	Useful Lives	2017			2016
		(in thousands)
Computer hardware	3 Years	$	1,435		$	1,293
Computer software	3 Years		463			354
Machinery and equipment	5 Years		—			177
Medical lab equipment	5 Years		7,145			4,678
General equipment	3 Years		—			59
Furniture and fixtures	5 Years		159			86
Leasehold improvements	Shorter of lease term or estimated useful life		763			520
Assets not yet placed in service			1,074			1,114
Total			11,039			8,281
Less: Accumulated depreciation			(3,767	)		(2,047	)
Property and equipment, net		$	7,272		$	6,234

Other Current Assets (Tables)

12 Months Ended

Dec. 31, 2017

Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]

Schedule of Other Current Assets

Other current assets consisted of the following:

	December 31,
	2017		2016
	(in thousands)
Reagents	$	231	$	322
Prepaid expenses		624		375
Prepaid income taxes		1,313		—
Marketable securities interest receivable		204		209
Other receivable		66		—
Total	$	2,438	$	906

Reporting Segment and Geographic Information (Tables)

12 Months Ended

Dec. 31, 2017

Segment Reporting [Abstract]

Summary of Revenue by Geographic Region

Revenue by region was as follows:

	December 31,
	2017		2016
	(in thousands)
Revenue:
United States	$	9,024	$	8,258
Foreign:
Canada		4,091		3,798
People's Republic of China ("PRC")		2,614		3,241
Other Countries		3,001		2,979
Total	$	18,730	$	18,276

Commitment and Contingencies (Tables)

12 Months Ended

Dec. 31, 2017

Commitments And Contingencies Disclosure [Abstract]

Future Minimum Payments under Non-Cancelable Operating Leases

Future minimum payments under non-cancelable operating leases as of December 31, 2017 are as follows:

	Amounts
Year ending December 31,	(in thousands)
2018	$	254
2019		181
2020		178
2021		165
Thereafter		134
Total minimum lease payments	$	912

Stockholders’/Members’ Equity (Tables)

12 Months Ended

Dec. 31, 2017

Equity [Abstract]

Summary of Units of Fulgent LLC Cancelled in Exchange for Shares of Common Stock

The following is a summary of the units of Fulgent LLC that were cancelled in exchange for shares of the Company’s common stock:

	Pre-Reorganization
	(in thousands)
Class D-1 preferred units		51,382
Class D-2 preferred units		15,395
Class D common units		2,500
Class D common units — profits interests		28,355
Total		97,632

- Definition

Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21506-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21553-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21475-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21521-112644

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21484-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21538-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21488-112644

+ Details

Equity-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2017

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Equity-Based Compensation

The Company has included equity-based compensation expense as part of cost of revenue and operating expenses in the accompanying consolidated statements of operations as follows:

	Year Ended December 31,
	2017		2016
	(in thousands)
Cost of revenue	$	479	$	754
Research and development		807		1,161
Selling and marketing		318		454
General and administrative		515		2,285
Total	$	2,119	$	4,654

Summary of Activity for Options to Acquire Common Shares

The following table summarizes activity for options to acquire shares of the Company’s common stock in the years ended December 31, 2017 and 2016:

	Number of Units/Shares Subject to Options (in thousands)			Weighted- Average Exercise Price		Weighted- Average Grant Date Fair Value		Weighted- Average Remaining Contractual Life (in years)		Aggregate Intrinsic Value (in thousands) (1)
Balance at December 31, 2015		274		$	0.38				9.8	$	645
Authorized		—
Granted		324		$	1.18	$	7.94
Exercised		—
Canceled		(42	)	$	0.38
Balance at December 31, 2016		556		$	0.85				9.0	$	5,976
Authorized		—
Granted		—
Exercised		(81	)	$	0.38	$	4.19				578
Canceled		(10	)	$	4.91	$	6.32
Balance at December 31, 2017		465		$	0.84				8.0	$	1,785
Exercisable as of December 31, 2017		201		$	0.77				8.0	$	779

(1)	Aggregate intrinsic value is calculated as the difference between (i) the exercise price of options that, as of the applicable date, have an exercise price in excess of the fair value of the Company’s common stock, and (ii) the fair value of the Company’s common stock as of the applicable date.

Summary of Activity for RSUs Relating to Shares of Company's Common Stock

The following table summarizes activity for RSUs relating to shares of the Company’s common stock in the years ended December 31, 2017 and 2016:

	Number of Shares (in thousands)			Weighted-Average Grant Date Fair Value
Balance at December 31, 2015		—			—
Granted		364		$	9.69
Vested and settled		—
Forfeited		(2	)		9.02
Balance at December 31, 2016		362		$	9.69
Granted		708		$	5.09
Vested and settled		(90	)	$	9.66
Forfeited		(43	)	$	9.33
Balance at December 31, 2017		937		$	7.39

Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Options to Acquire Shares of Company's Common Stock

	Year Ended December 31,
	2016
Expected term (in years)		6.1
Risk-free interest rates		1.4	%
Dividend yield		—
Expected volatility		95.6	%

Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Options to Acquire Common Stock Granted to Non-Employees

The table below sets forth the weighted-average assumptions used in the Black-Scholes option-pricing model to estimate the fair value of options to acquire shares of the Company’s common stock (or, prior to the Reorganization, options to acquire common units of Fulgent LLC) granted to non-employees during the years ended December 31, 2016. The Company did not grant any options to acquire shares of the Company’s common stock to non-employees during the year ended December 31, 2017.

	Year Ended December 31,
	2016
Expected term (in years)		10
Risk-free interest rates		1.6	%
Dividend yield		—
Expected volatility		96.9	%

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Income Tax Expense (Benefit)

Income tax expense (benefit) consisted of the following:

	Year Ended December 31,
	2017			2016
	(in thousands)
Current:
Federal	$	(599	)	$	616
State		(80	)		58
Total Current		(679	)		674
Deferred:
Federal		(300	)		295
State		(36	)		(49	)
Change in valuation allowance		—			—
Total Deferred		(336	)		246
Total income tax expense (benefit)	$	(1,015	)	$	920

Reconciliation of Difference between Federal Statutory Income Tax Rate and Effective Income Tax Rate

Reconciliation of the difference between the federal statutory income tax rate and the effective income tax rate is as follows:

	Year Ended December 31,
	2017			2016

Tax provision at federal statutory rate		34.00	%		34.00	%
State taxes		0.78	%		1.98	%
Other		1.54	%		0.16	%
Impact of tax reform (1)		-0.02	%
Stock based compensation		-2.13	%
Recognition of pre-merger temporary differences					-19.51	%
LLC income not subject to corporate taxes					-37.23	%
Tax provision		34.17	%		-20.60	%
________________
(1) The effective tax rate for the year ended December 31, 2017 includes the Company’s estimate of the effect of the 2017 Tax Act, which primarily relates to the remeasurment of existing deferred taxes as a result of the change to the U.S. federal corporate income tax rate.

Summary of Elements of Deferred Tax Assets (Liabilities)

The following table summarizes the elements of the deferred tax assets (liabilities):

	Year Ended December 31,
	2017			2016
	(in thousands)
Deferred tax assets
Accrued vacation and other accrued expenses	$	96		$	69
Provision for bad debts		65			54
Net operating losses		148
Stock based compensation		594			603
Unrealized loss on investments		37			58
State income taxes		6			20
Equity Method Investment		118
Gross deferred tax assets		1,064			804
Less: Valuation allowance		(118	)		-
Net deferred tax assets		946			804
Deferred tax liabilities
Depreciation		820			993
Total deferred tax liabilities		820			993
Net deferred tax assets (liabilities)	$	126		$	(189	)

Income (Loss) Per Share (Tables)

12 Months Ended

Dec. 31, 2017

Earnings Per Share [Abstract]

Reconciliation of the Basic and Diluted Income (Loss) Per Share Computations

	Years Ended
	2017								2016
	Continuing Operations			Discontinued Operations		Total			Continuing Operations			Discontinued Operations		Total
	(in thousands, except per share data)
Income (loss)	$	(2,510	)	$	—	$	(2,510	)	$	(5,388	)	$	41	$	(5,347	)
Deemed dividend on redemption of Class D-1 preferred units		—			—		—		$	(3,727	)		—	$	(3,727	)
Distribution to Class D-1 preferred unitholder		—			—		—		$	(4,592	)		—	$	(4,592	)
Income (loss) allocable to common stockholders	$	(2,510	)	$	—	$	(2,510	)	$	(13,707	)	$	41	$	(13,666	)
Income (loss) allocated to common stockholders	$	(2,510	)						$	(13,707	)
Income (loss) allocated to Class P common units		—								—			18
Income (loss) allocated to Class P preferred units		—								—			23
Weighted-average common shares - outstanding, basic and diluted		17,739								13,710			—
Weighted-average Class P common units - profits interests - outstanding, basic and diluted													10,123
Weighted-average Class P preferred units - outstanding, basic and diluted													13,238
Income (loss) per Class P common units - profits interests, basic and diluted												$	—
Income (loss) per Class P preferred units, basic and diluted												$	—
Income (loss) per common share from continuing operations, basic and diluted	$	(0.14	)						$	(1.00	)

Anti-dilutive Securities Excluded from Calculation of Diluted Income (Loss) Per Share

The following securities have been excluded from the calculation of diluted income (loss) per share for all periods presented because their effect would have been anti-dilutive:

	Years Ended
	2017		2016
	(in thousands)
Options		464		490
RSUs		526		79

Equity Method Investments (Tables)

12 Months Ended

Dec. 31, 2017

Equity Method Investments And Joint Ventures [Abstract]

Schedule of Equity Method Investments

The Company had no equity method investments as of December 31, 2016. Equity method investments as of December 31, 2017 consisted of the following:

	Carrying Value		Ownership Percentage
	(in thousands)
FF Gene Biotech	$	1,937		30	%
Total equity method investments	$	1,937		30	%

Summary of Financial Information for Equity Method Investees

Summary financial information for FF Gene Biotech is as follows:

	December 31,
	2017		2016
Consolidated Balance Sheet Data:	(in thousands)
Current Assets	$	2,474	$	830
Non-Current Assets		4,851		4,593
Current Liabilities		942		119
Non-Current Liabilities		—		—
Minority Interest		—		—
Stockholders' Equity		6,383		5,304

	Years Ended December 31,
	2017			2016
Consolidated Statement of Operations Data:	(in thousands)
Net Sales	$	90		$	—
Gross Profit		10			—
Net Loss		(2,318	)		(662	)
Share of loss from investments accounted for using the equity method (1)		(524	)		—

(1) The Company's share of loss is based on pro-rated net loss beginning April 25, 2017, the date on which the Company entered into the JV Agreement.

Selected Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2017

Quarterly Financial Information Disclosure [Abstract]

Unaudited Quarterly Data

	Three Months Ended
	Dec. 31, 2017			Sept. 30, 2017			June 30, 2017			Mar. 31, 2017		Dec. 31, 2016		Sept. 30, 2016			June 30, 2016			Mar. 31, 2016
	(dollars in thousands, except per share data)
Statement of Operations Data:
Revenue	$	4,281		$	4,503		$	4,640		$	5,306	$	5,854	$	5,011		$	3,971		$	3,440
Cost of revenue		2,545			2,268			1,879			1,859		1,863		2,143			1,411			1,304
Gross profit		1,736			2,235			2,761			3,447		3,991		2,868			2,560			2,136
Operating expenses:
Research and development		1,324			1,128			920			851		818		1,523			656			561
Selling and marketing		1,080			1,383			851			891		798		893			477			301
General and administrative		1,402			1,205			1,140			1,486		1,116		1,147			457			1,889
Total operating expenses		3,806			3,716			2,911			3,228		2,732		3,563			1,590			2,751
Operating income (loss)		(2,070	)		(1,481	)		(150	)		219		1,259		(695	)		970			(615	)
Interest and other income (expense)		97			145			120			119		57		5			(5,462	)		13
Income (loss) before income taxes and equity loss in investee		(1,973	)		(1,336	)		(30	)		338		1,316		(690	)		(4,492	)		(602	)
Provision for income taxes		(596	)		(415	)		(110	)		106		503		417			-			-
Income (loss) before equity loss in investee		(1,377	)		(921	)		80			232		813		(1,107	)		(4,492	)		(602	)
Equity loss in investee		(247	)		(172	)		(105	)		-		-		-			-			-
Net income (loss)	$	(1,624	)	$	(1,093	)	$	(25	)	$	232	$	813	$	(1,107	)	$	(4,492	)	$	(602	)

Net income (loss) per common share:
Basic	$	(0.09	)	$	(0.06	)	$	-		$	0.01	$	0.05	$	(0.44	)	$	(5.49	)	$	(0.02	)
Diluted	$	(0.09	)	$	(0.06	)	$	-		$	0.01	$	0.05	$	(0.44	)	$	(5.49	)	$	(0.02	)

Overview and Basis of Presentation - Additional Information (Details) - USD ($)				12 Months Ended
	Oct. 07, 2016	Oct. 04, 2016	Sep. 30, 2016	Dec. 31, 2017	Dec. 31, 2016
Description Of Business And Basis Of Presentation [Line Items]
Place of incorporation				Delaware
Date of incorporation				May 13, 2016
Date of corporate name change				Aug. 02, 2016
Income (loss) from discontinued operations				$ 0	$ 41,000
Reclassification of Current Assets
Description Of Business And Basis Of Presentation [Line Items]
Equity method investment					(2,810,000)
Reclassification of Non-current Assets
Description Of Business And Basis Of Presentation [Line Items]
Equity method investment					$ 2,810,000
Common Stock \| IPO
Description Of Business And Basis Of Presentation [Line Items]
Stock issued and sold (in shares)		4,830,000
Stock price per share		$ 9.00
Proceeds from issuance of shares		$ 36,000,000
Underwriting discounts and commissions		3,000,000
Other offering expenses		$ 4,400,000
Common Stock \| Over Allotment Option
Description Of Business And Basis Of Presentation [Line Items]
Stock issued and sold (in shares)	630,000
Restricted Stock Units (RSUs)
Description Of Business And Basis Of Presentation [Line Items]
Units cancelled in exchange for restricted stock units relating to company’s common stock					0
Fulgent Therapeutics LLC
Description Of Business And Basis Of Presentation [Line Items]
Ownership percentage in subsidiary				100.00%
Units cancelled in exchange for one share of common stock			7.6	7.6
Share of common stock exchanged for seven point six units			1	1
Gain (loss) on reorganization				$ 0
Fulgent Therapeutics LLC \| Restricted Stock Units (RSUs)
Description Of Business And Basis Of Presentation [Line Items]
Units cancelled in exchange for restricted stock units relating to company’s common stock				65,789
Fulgent Therapeutics LLC \| Class D-1 Preferred Units
Description Of Business And Basis Of Presentation [Line Items]
Number of common stock shares exchanged for cancelled units				6,760,733
Fulgent Therapeutics LLC \| Class D-2 Preferred Units
Description Of Business And Basis Of Presentation [Line Items]
Number of common stock shares exchanged for cancelled units				2,025,623
Fulgent Therapeutics LLC \| Class D Common Units
Description Of Business And Basis Of Presentation [Line Items]
Number of common stock shares exchanged for cancelled units				4,059,900
Minimum
Description Of Business And Basis Of Presentation [Line Items]
Estimated useful lives of fixed assets				3 years
Maximum
Description Of Business And Basis Of Presentation [Line Items]
Estimated useful lives of fixed assets				5 years
Maximum \| Fulgent Therapeutics LLC
Description Of Business And Basis Of Presentation [Line Items]
Options to acquire units cancelled in exchange for company’s common stock				591,112

Overview and Basis of Presentation - Major Components of Statements of Operations Data Comprising Income (Loss) from Discontinued Operations (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2016 USD ($)
Operating expenses:
Research and development	$ 350
General and administrative	9
Total operating expenses	359
Operating loss	(359)
Other income	400
Income	$ 41

- Definition

Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details

Summary of Significant Accounting Policies - Roll-Forward of Activity in Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Receivables [Abstract]
Allowance for doubtful accounts at beginning of year	$ 151	$ 75
Bad debt expense	160	103
Deductions	(24)	(27)
Allowance for doubtful accounts at end of year	$ 287	$ 151

Summary of Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2017 USD ($) Customer Segment	Dec. 31, 2016 Customer	Jan. 01, 2018 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Impairment losses of long-lived assets	$ 0
Number of reporting segments \| Segment	1
Shipping and handling fees incurred	$ 0
Federal and state tax expense (benefit) prior to reorganization.	$ 0
Accounting Standards Update 2014-09
Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle, adjustment to accumulated deficit and accounts receivable			$ 327,000,000
Computer Software
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives of fixed assets	3 years
Minimum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives of fixed assets	3 years
Maximum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives of fixed assets	5 years
Customer Concentration Risk \| Revenues
Summary Of Significant Accounting Policies [Line Items]
Number of customers comprised more than 10% of total accounts receivable or revenues \| Customer	3	1
Concentration risk, percentage		15.00%
Customer Concentration Risk \| Revenues \| Customer One [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	14.00%
Customer Concentration Risk \| Revenues \| Customer Two [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	12.00%
Customer Concentration Risk \| Revenues \| Customer Three [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	10.00%
Customer Concentration Risk \| Accounts Receivable
Summary Of Significant Accounting Policies [Line Items]
Number of customers comprised more than 10% of total accounts receivable or revenues \| Customer	1	4
Customer Concentration Risk \| Accounts Receivable \| Customer One [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	13.00%	12.00%
Customer Concentration Risk \| Accounts Receivable \| Customer Two [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage		11.00%
Customer Concentration Risk \| Accounts Receivable \| Customer Three [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage		12.00%
Customer Concentration Risk \| Accounts Receivable \| Customer Four [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage		11.00%

Marketable Securities - Summary of Marketable Securities (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Schedule of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	$ 35,039	$ 38,728
Marketable securities, Unrealized Gains	2	3
Marketable securities, Unrealized Loses	(164)	(163)
Marketable securities, Aggregate Fair Value	34,877	38,568
Short-Term Marketable Securities
Schedule of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	20,040	12,988
Marketable securities, Unrealized Gains	2
Marketable securities, Unrealized Loses	(48)	(17)
Marketable securities, Aggregate Fair Value	19,994	12,971
Less: Cash equivalents	(723)	(1,580)
Short-Term Marketable Securities \| Money Market Accounts
Schedule of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	723	1,580
Marketable securities, Aggregate Fair Value	723	1,580
Short-Term Marketable Securities \| Corporate Debt Securities
Schedule of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	20,040	12,988
Marketable securities, Unrealized Gains	2
Marketable securities, Unrealized Loses	(48)	(17)
Marketable securities, Aggregate Fair Value	19,994	12,971
Long-Term Marketable Securities
Schedule of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	14,999	25,740
Marketable securities, Unrealized Gains		3
Marketable securities, Unrealized Loses	(116)	(146)
Marketable securities, Aggregate Fair Value	14,883	25,597
Long-Term Marketable Securities \| Corporate Debt Securities
Schedule of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	14,999	25,740
Marketable securities, Unrealized Gains		3
Marketable securities, Unrealized Loses	(116)	(146)
Marketable securities, Aggregate Fair Value	$ 14,883	$ 25,597

Marketable Securities - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Investments Debt And Equity Securities [Abstract]
Marketable securities less than one year	$ 19,994,000	$ 12,971,000
Marketable securities greater than one year and less than five years	14,883,000	25,597,000
Gross unrealized loss	$ 164,000	$ 163,000

- Definition

Investments in debt and equity securities which are categorized neither as held-to-maturity nor trading and which are intended to be sold or mature more than one year from the balance sheet date or operating cycle, if longer. Such securities are reported at fair value; unrealized gains (losses) related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain (loss) of an Available-for-sale security that is designated as being hedged in a fair value hedge is recognized in earnings during the period of the hedge, as are other than temporary declines in fair value below the cost basis for investments in equity securities and debt securities that an entity intends to sell or it is more likely than not that it will be required to sell before the recovery of its amortized cost basis. Other than temporary declines in fair value below the cost basis for debt securities categorized as Available-for-sale that an entity does not intend to sell and for which it is not more likely than not that the entity will be required to sell before the recovery of its amortized cost basis are bifurcated into credit losses and losses related to all other factors. Other than temporary declines in fair value below cost basis related to credit losses are recognized in earnings, and losses related to all other factors are recognized in other comprehensive income.

+ References + Details

Fair Value Measurements - Information about Financial Assets Measured at Fair Value on Recurring Basis Based on Three-Tier Fair Value Hierarchy (Details) - Fair Value Measurements Recurring - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	$ 35,600	$ 40,148
Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	723	1,580
Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	34,877	38,568
Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	34,877	38,568
Corporate Debt Securities \| Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	34,877	38,568
Money Market Accounts
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	723	1,580
Money Market Accounts \| Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	$ 723	$ 1,580

Fair Value Measurements - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Fair value asset, investments measured using unobservable inputs	$ 0	$ 0
Fair value assets, transfers between levels, amount	0	0
Unrealized losses for securities in an unrealized loss position for more than 12 months	107,000
Other-than-temporary impairment losses related to marketable securities	$ 0	$ 0

Fixed Assets - Major Classes of Fixed Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 11,039	$ 8,281
Less: Accumulated depreciation	(3,767)	(2,047)
Fixed assets, net	7,272	6,234
Computer Hardware
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 1,435	1,293
Useful life in years	3 years
Computer Software
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 463	354
Useful life in years	3 years
Machinery and Equipment
Property Plant And Equipment [Line Items]
Fixed assets, gross		177
Useful life in years	5 years
Medical Lab Equipment
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 7,145	4,678
Useful life in years	5 years
General Equipment
Property Plant And Equipment [Line Items]
Fixed assets, gross		59
Useful life in years	3 years
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 159	86
Useful life in years	5 years
Leasehold Improvements
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 763	520
Useful life in years	Shorter of lease term or estimated useful life
Assets Not Yet Placed in Service
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 1,074	$ 1,114

Fixed Assets - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Property Plant And Equipment [Abstract]
Depreciation expense on fixed assets	$ 1,728	$ 1,170

Other Current Assets - Schedule of Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Reagents	$ 231	$ 322
Prepaid expenses	624	375
Prepaid income taxes	1,313
Marketable securities interest receivable	204	209
Other receivable	66
Total	$ 2,438	$ 906

Reporting Segment and Geographical Information - Additional Information (Details)	12 Months Ended
	Dec. 31, 2017 Segment
Segment Reporting [Abstract]
Number of reporting segments	1

Reporting Segment and Geographical Information - Summary of Revenue by Geographic Region (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Segment Reporting Information [Line Items]
Revenue	$ 4,281	$ 4,503	$ 4,640	$ 5,306	$ 5,854	$ 5,011	$ 3,971	$ 3,440	$ 18,730	$ 18,276
United States
Segment Reporting Information [Line Items]
Revenue									9,024	8,258
Canada
Segment Reporting Information [Line Items]
Revenue									4,091	3,798
People's Republic of China ("PRC")
Segment Reporting Information [Line Items]
Revenue									2,614	3,241
Other Countries
Segment Reporting Information [Line Items]
Revenue									$ 3,001	$ 2,979

Commitments and Contingencies - Additional Information (Details) - USD ($)		12 Months Ended
	Jan. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Commitments And Contingencies [Line Items]
Operating leases, rent expense		$ 250,000	$ 204,000
Reagents and Equipment
Commitments And Contingencies [Line Items]
Purchase obligations		$ 1,700,000
California \| Subsequent Event
Commitments And Contingencies [Line Items]
Operating leases, rent expense	$ 269,000
Lease commencement date	Feb. 01, 2018
Lease expiration date	Jan. 31, 2021
Non Cancelable Operating Lease
Commitments And Contingencies [Line Items]
Operating leases, renewal term		3 years

Commitments and Contingencies - Future Minimum Payments under Non-Cancelable Operating Leases (Details) $ in Thousands	Dec. 31, 2017 USD ($)
Commitments And Contingencies Disclosure [Abstract]
2018	$ 254
2019	181
2020	178
2021	165
Thereafter	134
Total minimum lease payments	$ 912

Stockholders' / Members' Equity - Additional Information (Details)				1 Months Ended	12 Months Ended
	Sep. 30, 2016 shares	May 17, 2016 USD ($) shares	May 13, 2016 USD ($) shares	May 31, 2016 USD ($) shares	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 31, 2016 USD ($) $ / shares shares	May 31, 2017 Vote $ / shares shares	Apr. 30, 2017 shares
Class Of Stock [Line Items]
Unrealized holding gains (losses) on marketable securities					$ 37,000	$ 58,000
Common stock, shares authorized \| shares					50,000,000	200,000,000	50,000,000	200,000,000
Common stock, par value \| $ / shares					$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized \| shares					1,000,000	1,000,000	1,000,000
Preferred stock, par value \| $ / shares					$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares outstanding \| shares					0	0
Tax distribution to former LLC members						$ 1,300,000
Return of capital contribution						4,600,000
Distributions made					$ 0
Aggregate purchase price						26,980,000
Class D-1 Preferred Units
Class Of Stock [Line Items]
Deemed dividend						3,727,000
Class D-2 Preferred Units
Class Of Stock [Line Items]
Issuance costs of units						185,000
Xi Long Financing
Class Of Stock [Line Items]
Aggregate purchase price			$ 12,000,000
Xi Long Financing \| Class D-1 Preferred Units
Class Of Stock [Line Items]
Number of units acquired \| shares			4,618,421
Deemed dividend				$ 3,700,000
Xi Long Financing \| Class D Common Units
Class Of Stock [Line Items]
Number of units acquired \| shares			5,644,737
Xi Long Financing \| Class D-2 Preferred Units
Class Of Stock [Line Items]
Number of units acquired \| shares		5,131,579
Aggregate purchase price		$ 15,200,000
Issuance costs of units				185,000
Net proceeds from issuance of units				$ 15,000,000
Conversion of stock, shares converted \| shares				2,025,623
Issuance of preferred units, shares \| shares				15,394,737
Issuance of preferred units, value				$ 32,600,000
Aggregate purchase price				27,200,000
Difference amount of fair value and aggregate consideration paid				$ 5,500,000
Fulgent Therapeutics LLC
Class Of Stock [Line Items]
Units cancelled in exchange for one share of common stock \| shares	7.6				7.6
Share of common stock exchanged for seven point six units \| shares	1				1
Common Stock
Class Of Stock [Line Items]
Number of vote per share held \| Vote							1
Common Stock \| Reorganization
Class Of Stock [Line Items]
Cancelled in exchange for common units \| shares					12,846,256
Common Stock and Additional Paid-in Capital \| Reorganization
Class Of Stock [Line Items]
Conversion of members' interests						$ 72,000,000

Stockholders' / Members' Equity - Summary of Units of Fulgent LLC Cancelled in Exchange for Shares of Common Stock (Details)	12 Months Ended
	Dec. 31, 2017 shares
Class Of Stock [Line Items]
Pre-Reorganization	97,632,000
Class D-1 Preferred Units
Class Of Stock [Line Items]
Pre-Reorganization	51,382,000
Class D-2 Preferred Units
Class Of Stock [Line Items]
Pre-Reorganization	15,395,000
Class D Common Units
Class Of Stock [Line Items]
Pre-Reorganization	2,500,000
Class D Common Units - Profit Interests
Class Of Stock [Line Items]
Pre-Reorganization	28,355,000

Equity-Based Compensation - Additional Information (Details)	12 Months Ended
	Dec. 31, 2017 USD ($) shares	Dec. 31, 2016 USD ($) shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity-based compensation expense	$ 2,119,000	$ 4,654,000
Initial public offerings completion date	Oct. 04, 2016
Marketability discount	20.00%
Fulgent Therapeutics LLC
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity-based compensation expense	$ 1,400,000
Cancellation of common stock ratio	0.1316
2015 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	4 years
Stock option expiration period	10 years
Equity-based compensation expense	$ 0
2015 Equity Incentive Plan \| Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity-based compensation expense	$ 1,100,000
2016 Omnibus Incentive Plan \| Class D Common Units \| Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Cancellation of common stock ratio	0.1316
2016 Omnibus Incentive Plan \| Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Remaining share availbale for grants \| shares	487,826
2016 Omnibus Incentive Plan \| Employees Directors and Consultants \| Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares available for issuance under the plan \| shares	2,038,480
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected to be recognized, weighted-average period	3 years 4 months 24 days
Units granted \| shares		0
Total compensation cost not yet recognized on grant date	$ 4,800,000	$ 3,500,000
Compensation cost not yet recognized on grant date, period for recognition	4 years
Unrecognized compensation expense	$ 6,200,000
Restricted Stock Units (RSUs) \| Fulgent Therapeutics LLC
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Units granted \| shares	65,789
Restricted Stock Units (RSUs) \| 2015 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	4 years
Restricted Stock Units (RSUs) \| 2016 Omnibus Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Units granted \| shares	708,000	364,000
Restricted Stock Units (RSUs) \| 2016 Omnibus Incentive Plan \| Class D Common Units \| Fulgent Therapeutics LLC
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Cancellation of common stock ratio	0.1316
Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option granted \| shares	0	324,000
Total fair value of options vested	$ 1,100,000	$ 263,000
Unrecognized compensation expense	$ 505,000
Expected to be recognized, weighted-average period	1 year 9 months 18 days
Shares Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Units granted \| shares		329,000
Common stock grant date fair value		$ 1,600,000

Equity-Based Compensation - Summary of Equity-Based Compensation Expenses as Part of Cost of Revenue and Operating Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	$ 2,119	$ 4,654
Cost of Revenue
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	479	754
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	807	1,161
Selling and Marketing
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	318	454
General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	$ 515	$ 2,285

Equity-Based Compensation - Summary of Activity for Options to Acquire Common Shares (Details) - Options - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Units/Shares Subject to Options, Beginning Balance	556,000	274,000
Number of Units/Shares Subject to Options, Granted	0	324,000
Number of Units/Shares Subject to Options, Exercised	(81,000)
Number of Units/Shares Subject to Options, Canceled	(10,000)	(42,000)
Number of Units/Shares Subject to Options, Ending Balance	465,000	556,000	274,000
Number of Units/Shares Subject to Options, Exercisable	201,000
Weighted-Average Exercise Price Per Shares, Beginning Balance	$ 0.85	$ 0.38
Weighted-Average Exercise Price Per Shares, Granted		1.18
Weighted-Average Exercise Price Per Shares, Exercised	0.38
Weighted-Average Exercise Price Per Shares, Canceled	4.91	0.38
Weighted-Average Exercise Price Per Shares, Ending Balance	0.84	0.85	$ 0.38
Weighted-Average Exercise Price Per Shares, Exercisable	0.77
Weighted-Average Grant Date Fair Value, Granted		$ 7.94
Weighted-Average Grant Date Fair Value, Exercised	4.19
Weighted-Average Grant Date Fair Value, Canceled	$ 6.32
Weighted-Average Remaining Contractual Life (in years)	8 years	9 years	9 years 9 months 18 days
Weighted-Average Remaining Contractual Life (in years), Exercisable	8 years
Aggregate Intrinsic Value, Balance	$ 1,785	$ 5,976	$ 645
Aggregate Intrinsic Value, Exercised	578
Aggregate Intrinsic Value, Exercisable	$ 779

Equity-Based Compensation - Summary of Activity for RSUs Relating to Shares of Company's Common Stock (Details) - Restricted Stock Units (RSUs) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Number of Shares
Number of Shares, Granted		0
2016 Omnibus Incentive Plan
Number of Shares
Number of Shares, Beginning Balance	362,000
Number of Shares, Granted	708,000	364,000
Number of Shares, Vested and settled	(90,000)
Number of Shares, Forfeited	(43,000)	(2,000)
Number of Shares, Ending Balance	937,000	362,000
Weighted-Average Grant-Date Fair Value, Balance	$ 9.69
Weighted-Average Grant-Date Fair Value, Granted	5.09	$ 9.69
Weighted-Average Grant-Date Fair Value, Vested and settled	9.66
Weighted-Average Grant-Date Fair Value, Forfeited	9.33	9.02
Weighted-Average Grant-Date Fair Value, Balance	$ 7.39	$ 9.69

Equity-Based Compensation - Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Options to Acquire Shares of Company's Common Stock (Details) - Options	12 Months Ended
	Dec. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 years 1 month 6 days
Risk-free interest rates	1.40%
Expected volatility	95.60%

Equity-Based Compensation - Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Options to Acquire Common Stock Granted to Non-Employees (Details)	12 Months Ended
	Dec. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Expected term (in years)	10 years
Risk-free interest rates	1.60%
Expected volatility	96.90%

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended						12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Taxes [Line Items]
Income tax expense	$ (596,000)	$ (415,000)	$ (110,000)	$ 106,000	$ 503,000	$ 417,000		$ (1,015,000)	$ 920,000
Net deferred tax asset	946,000				804,000			$ 946,000	804,000
Net deferred tax liability					189,000				$ 189,000
Federal statutory rate								34.00%	34.00%
Tax Cuts and Jobs Act of 2017, income tax expense related to revaluation of net deferred tax assets								$ 22,000
Tax Cuts and Jobs Act of 2017, unrepatriated foreign earnings								0
Tax-related interests or penalties accrued	0				0			$ 0	$ 0
Maximum
Income Taxes [Line Items]
Federal statutory rate								35.00%
Scenario, Plan [Member]
Income Taxes [Line Items]
Federal statutory rate							21.00%
State [Member]
Income Taxes [Line Items]
Net deferred tax asset	90,000				54,000	86,000		$ 90,000	54,000
Federal [Member]
Income Taxes [Line Items]
Net deferred tax asset	$ 36,000							$ 36,000
Net deferred tax liability					$ 243,000	$ 503,000			$ 243,000

Income Taxes - Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	3 Months Ended						12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2017	Dec. 31, 2016
Current:
Federal							$ (599)	$ 616
State							(80)	58
Total Current							(679)	674
Deferred:
Federal							(300)	295
State							(36)	(49)
Total Deferred							(336)	246
Total income tax expense (benefit)	$ (596)	$ (415)	$ (110)	$ 106	$ 503	$ 417	$ (1,015)	$ 920

Income Taxes - Reconciliation of Difference between Federal Statutory Income Tax Rate and Effective Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Tax provision at federal statutory rate	34.00%	34.00%
State taxes	0.78%	1.98%
Other	1.54%	0.16%
Impact of tax reform	(0.02%)
Stock based compensation	(2.13%)
Recognition of pre-merger temporary differences		(19.51%)
LLC income not subject to corporate taxes		(37.23%)
Tax provision	34.17%	(20.60%)

Income Taxes - Summary of Elements of Deferred Tax Assets (Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets
Accrued vacation and other accrued expenses	$ 96	$ 69
Provision for bad debts	65	54
Net operating losses	148
Stock based compensation	594	603
Unrealized loss on investments	37	58
State income taxes	6	20
Equity Method Investment	118
Gross deferred tax assets	1,064	804
Less: Valuation allowance	(118)
Net deferred tax assets	946	804
Deferred tax liabilities
Depreciation	820	993
Total deferred tax liabilities	820	993
Net deferred tax assets	$ 126
Net deferred tax liabilities		$ (189)

Income (Loss) Per Share - Reconciliation of the Basic and Diluted Income (Loss) Per Share Computations (Details) - USD ($) $ / shares in Units, shares in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Earnings Per Share Basic And Diluted [Line Items]
Income (loss), continuing operations									$ (2,510,000)	$ (5,388,000)
Income (loss) from discontinued operations									0	41,000
Net income (loss)	$ (1,624,000)	$ (1,093,000)	$ (25,000)	$ 232,000	$ 813,000	$ (1,107,000)	$ (4,492,000)	$ (602,000)	(2,510,000)	(5,347,000)
Income (loss) allocable to common stockholders									$ (2,510,000)	$ (13,666,000)
Basic and Diluted									17,739	13,710
Continuing Operations
Earnings Per Share Basic And Diluted [Line Items]
Income (loss) allocable to common stockholders									$ (2,510,000)	$ (13,707,000)
Income (loss) allocated to common stockholders									$ (2,510,000)	$ (13,707,000)
Basic and Diluted									17,739	13,710
Income (loss) per common share from continuing operations, basic and diluted									$ (0.14)	$ (1.00)
Discontinued Operations
Earnings Per Share Basic And Diluted [Line Items]
Income (loss) allocable to common stockholders										$ 41,000
Class D-1 Preferred Units
Earnings Per Share Basic And Diluted [Line Items]
Deemed dividend on redemption of Class D-1 preferred units										(3,727,000)
Distribution to Class D-1 preferred unitholder										(4,592,000)
Class D-1 Preferred Units \| Continuing Operations
Earnings Per Share Basic And Diluted [Line Items]
Distribution to Class D-1 preferred unitholder										(4,592,000)
Class P Common Units \| Discontinued Operations
Earnings Per Share Basic And Diluted [Line Items]
Income (loss) allocated to common units										$ 18,000
Weighted-average Class P common units - profits interests - outstanding, basic and diluted										10,123
Class P Preferred Units \| Discontinued Operations
Earnings Per Share Basic And Diluted [Line Items]
Income (loss) allocated to preferred units										$ 23,000
Basic and Diluted										13,238

Income (Loss) Per Share - Anti-dilutive Securities Excluded from Calculation of Diluted Income (Loss) Per Share (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from continuing operations of diluted income (loss) per share	464	490
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from continuing operations of diluted income (loss) per share	526	79

Retirement Plans - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Defined Benefit Plan Disclosure [Line Items]
Company matching contributions to the 401(k) plan	$ 108,000	$ 86,000
Maximum
Defined Benefit Plan Disclosure [Line Items]
Employer matching contribution, percent of match	3.00%

Related Party - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Xilong Scientific
Related Party Transaction [Line Items]
Ownership percentage	11.00%
Fulgent Pharma
Related Party Transaction [Line Items]
Due from related parties	$ 3,000	$ 0
Dr. Han Lin Gao \| FF Gene Biotech \| FJIP
Related Party Transaction [Line Items]
Ownership percentage	25.00%
Research Testing Services
Related Party Transaction [Line Items]
Revenue from related parties	$ 0	150,000
Foundation
Related Party Transaction [Line Items]
Revenue from related parties	22,000	28,000
Due from related parties	0	0
University
Related Party Transaction [Line Items]
Revenue from related parties	82,600	353,000
Due from related parties	$ 40,000	$ 29,550

Equity Method Investments - Additional Information (Details)	1 Months Ended	3 Months Ended
	Apr. 30, 2017 CNY (¥)	Sep. 30, 2017 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2017 CNY (¥)	Dec. 31, 2016 USD ($)
Schedule Of Equity Method Investments [Line Items]
Contribution to be made in joint venture \| $			$ 1,937,000		$ 0
Ownership interest to be made in joint venture			30.00%	30.00%
FF Gene Biotech
Schedule Of Equity Method Investments [Line Items]
Contribution to be made in joint venture	¥ 60,000,000		$ 1,937,000
Contribution period in joint venture	3 years
Ownership interest to be made in joint venture	30.00%		30.00%	30.00%
Contributions remain for joint venture			$ 6,700,000	¥ 43,600,000
FF Gene Biotech \| Equipment
Schedule Of Equity Method Investments [Line Items]
Contributions made to joint venture \| $		$ 2,500,000
Xilong Scientific \| FF Gene Biotech
Schedule Of Equity Method Investments [Line Items]
Contribution period in joint venture	3 years
Ownership interest to be made in joint venture	51.00%
Contribution to be made in joint venture \| ¥	¥ 102,000,000
FJIP \| FF Gene Biotech
Schedule Of Equity Method Investments [Line Items]
Contribution period in joint venture	5 years
Ownership interest to be made in joint venture	19.00%
Contribution to be made in joint venture \| ¥	¥ 19,000,000

Equity Method Investments - Schedule of Equity Method Investments (Details)	Dec. 31, 2017 USD ($)	Apr. 30, 2017 CNY (¥)	Dec. 31, 2016 USD ($)
Schedule Of Equity Method Investments [Line Items]
Carrying Value	$ 1,937,000		$ 0
Ownership Percentage	30.00%
FF Gene Biotech
Schedule Of Equity Method Investments [Line Items]
Carrying Value	$ 1,937,000	¥ 60,000,000
Ownership Percentage	30.00%	30.00%

Equity Method Investments - Summary of Financial Information for Equity Method Investees, Balance Sheet Data (Details) - FF Gene Biotech - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Schedule Of Equity Method Investments [Line Items]
Current Assets	$ 2,474	$ 830
Non-Current Assets	4,851	4,593
Current Liabilities	942	119
Non-Current Liabilities
Stockholders' Equity	$ 6,383	$ 5,304

Equity Method Investments - Summary of Financial Information for Equity Method Investees, Statement of Operations Data (Details) - USD ($) $ in Thousands	3 Months Ended			12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Schedule Of Equity Method Investments [Line Items]
Share of loss from investments accounted for using the equity method (1)	$ (247)	$ (172)	$ (105)	$ (524)	$ 0
FF Gene Biotech
Schedule Of Equity Method Investments [Line Items]
Net Sales				90
Gross Profit				10
Net Loss				(2,318)	$ (662)
Share of loss from investments accounted for using the equity method (1)				$ (524)

Selected Quarterly Financial Data (Unaudited) - Unaudited Quarterly Data (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Statement of Operations Data:
Revenue	$ 4,281	$ 4,503	$ 4,640	$ 5,306	$ 5,854	$ 5,011	$ 3,971	$ 3,440	$ 18,730	$ 18,276
Cost of revenue	2,545	2,268	1,879	1,859	1,863	2,143	1,411	1,304	8,551	6,722
Gross profit	1,736	2,235	2,761	3,447	3,991	2,868	2,560	2,136	10,179	11,554
Operating expenses:
Research and development	1,324	1,128	920	851	818	1,523	656	561	4,223	3,558
Selling and marketing	1,080	1,383	851	891	798	893	477	301	4,205	2,469
General and administrative	1,402	1,205	1,140	1,486	1,116	1,147	457	1,889	5,233	4,609
Total operating expenses	3,806	3,716	2,911	3,228	2,732	3,563	1,590	2,751	13,661	10,636
Operating income (loss)	(2,070)	(1,481)	(150)	219	1,259	(695)	970	(615)	(3,482)	918
Interest and other income (expense)	97	145	120	119	57	5	(5,462)	13	481	(5,386)
Income (loss) before income taxes and equity loss in investee	(1,973)	(1,336)	(30)	338	1,316	(690)	(4,492)	(602)	(3,001)	(4,468)
Provision for (benefit from) income taxes	(596)	(415)	(110)	106	503	417			(1,015)	920
Income (loss) before equity loss in investee	(1,377)	(921)	80	232	813	(1,107)	(4,492)	(602)	(1,986)	(5,388)
Equity loss in investee	(247)	(172)	(105)						(524)	0
Net income (loss)	$ (1,624)	$ (1,093)	$ (25)	$ 232	$ 813	$ (1,107)	$ (4,492)	$ (602)	$ (2,510)	$ (5,347)
Net income (loss) per common share:
Basic	$ (0.09)	$ (0.06)		$ 0.01	$ 0.05	$ (0.44)	$ (5.49)	$ (0.02)
Diluted	$ (0.09)	$ (0.06)		$ 0.01	$ 0.05	$ (0.44)	$ (5.49)	$ (0.02)